+

WO1996036358A1 - Composition et procede d'inhibition du rejet des greffons heterologues - Google Patents

Composition et procede d'inhibition du rejet des greffons heterologues Download PDF

Info

Publication number
WO1996036358A1
WO1996036358A1 PCT/US1996/006804 US9606804W WO9636358A1 WO 1996036358 A1 WO1996036358 A1 WO 1996036358A1 US 9606804 W US9606804 W US 9606804W WO 9636358 A1 WO9636358 A1 WO 9636358A1
Authority
WO
WIPO (PCT)
Prior art keywords
xenograft
antibody
donor
rejection
ser
Prior art date
Application number
PCT/US1996/006804
Other languages
English (en)
Inventor
Donald V. Cramer
Leonard Makowka
Guo-Du Wu
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Priority to EP96915749A priority Critical patent/EP0827409A1/fr
Publication of WO1996036358A1 publication Critical patent/WO1996036358A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Organ transplantation is becoming an increasingly effective medical therapy for the long-term treatment of many otherwise fatal diseases.
  • the major limitation to routine transplantation as a surgical procedure was that of organ rejection.
  • the development of powerful new immunosuppressive drugs has significantly improved organ graft survival.
  • the major factor currently acting to prevent those who need a transplant from getting one is an acute shortage of human donor organs. Those who do receive transplants are having to wait longer to find a suitable match, compromising their chances for optimum results, and sometimes, survival.
  • This shortage of donor tissue limits the application of transplantation to a small proportion of patients who could be expected to benefit from the operation and produces higher health care costs because of the requirement for continued intensive care of patients with chronic, terminal diseases.
  • Transplantation is by definition the placement of foreign tissue ("donor") into a host recipient, thus an immunological attack on the foreign tissue (“rejection”) is to be expected.
  • the vigor with which this immunological assault is mounted has been correlated with the genetic disparity of the donor/recipient species. The greater the genetic disparity, the swifter and more acute the immunological rejection. Accordingly, the rejection of xenografts is typically more vigorous than allografts.
  • Xenograft rejections have been classified into two general categories on the basis of this genetic disparity of the donor/recipient species and the rapidity of the graft rejection as compared to allograft rejection untreated recipients.
  • xenografts from genetically distant (“discordant") donors react by mounting a rapid, hyperacute rejection of the foreign graft.
  • This form of rejection is seen with pig-to-human xenogeneic transplants and is associated with the loss of the xenograft within a few minutes or hours.
  • This type of xenograft rejection has proven to be more difficult to control therapeutically than the accelerated rejection characteristic of xenogeneic transplants between concordant species, discussed below. Therefore, these species combinations have been less attractive as potential organ donors for humans.
  • the anti-xenograft antibodies are polyclonal or polyspecific, the changes are compatible with antibody binding to antigens expressed on the endothelium of the donor graft vessels and activation of the complement cascade.
  • hyperacute rejection of xenografts the antibodies are apparently immediately available to mount an attack which results in rejection. While, in the case of the accelerated rejection of xenografts, the antibodies which mediate rejection must first be manufactured.
  • Antibodies produced by the rat after transplant with hamster tissue display a pattern of reaction with heart membrane antigens in Western blots that is similar to that seen with the preformed antibodies. See, Cramer D. V., et al., Transplantation 54:403-408 (1992) .
  • Specie combinations that normally are characterized by an accelerated rejection reactions can also be shown to display hyperacute rejection following either sensitization of the recipient with donor tissue immunogen prior to transplant or by passive transfer of hyperimmune sera prior to transplant.
  • Immunizing recipient rats with hamster lymphocytes or hamster cardiac grafts prior to a hamster-to- rat xenogeneic transplant results in an antibody-mediated hyperacute rejection of hamster xenografts.
  • These hamster tissue immunogens reportedly stimulate a rapid rise in the normally low levels of IgM antibody that react with hamster lymphocytes and vascular endothelium and graft rejection follows.
  • the present invention provides novel and powerful immunological compositions and methods for inhibiting antibody-mediated rejection of xenografts by a transplant recipient.
  • pre-transplant treatment of the xenograft with these immunological compositions preferably supplemented by post-transplant therapeutic treatment of the xenograft recipient with these immunological compositions and, optionally, chemical immunosuppressive agents, prolonged survival of the graft can be achieved, providing the first, critical step to long-term xenograft survival.
  • This ability to intervene in the immune response to xenogeneic tissue opens the door to the use of xenografts as a meaningful alternative to the shortage of available allogeneic organs.
  • methods of inhibiting rejection of a donor xenograft by a recipient animal comprising modifying antigen expressed by cells of the xenograft, without causing lysis of the cells, to inhibit binding of recipient anti- donor xenograft antibody to said antigen, wherein said antigen present in unmodified form induces an antibody- mediated immune response in the recipient animal.
  • a preferred method of modifying such antigen, particularly those expressed by endothelial cells of the xenograft comprises contacting non-lytic, anti-donor xenograft antibody material with said antigen for a time, at a temperature, and at a pH suitable to bind the antibody material to the antigen.
  • Anti-donor xenograft antibody material also provided by the present invention is characterized as immunoreactive with antigen expressed by endothelial cells of the xenograft and capable of inhibiting antibody-mediated rejection of the xenograft by a recipient animal.
  • This invention also provided, for the first time, monoclonal antibodies that immunoreact with antigen expressed by endothelial cells of donor xenografts and which are capable of inducing antibody-mediated rejection of the xenograft.
  • monoclonal antibodies that immunoreact with antigen expressed by endothelial cells of donor xenografts and which are capable of inducing antibody-mediated rejection of the xenograft.
  • the present invention also provides methods of using the compositions of the present invention to isolate and further characterize the antigen(s) responsible for precipitating xenogeneic transplant rejection reaction.
  • Figure 1 is the nucleotide sequence of the variable heavy chain region of the rat anti-hamster xenograft monoclonal antibody designated HAR-1. The sequence of the
  • SAX oligonucleotide has been artificially included with the 5 ' end of the sequence.
  • the 5 ' untranslated region appears in lower case.
  • the boundaries for the framework and CDR regions are deduced from conventions estabilished by Kabat and Wu for mouse and human immunoglobulin and are indicated above the sequence. Primers which were used to generate this and other sequences are labeled and designated by underline.
  • Figure 2 shows the cDNA nucleotide sequence of the variable heavy chain segment of the rat anti-hamster xenograft monoclonal antibody designated HAR-1 aligned with its germ-line counterpart VH1.1 obtained by genomic amplification of newborn LEW rat liver DNA.
  • the two sequences are 99.2% (351/354 nucleotides) homologous.
  • HAR-1 cDNA sequence differs at three nucleotides from the germ ⁇ line sequence. The first difference leads to a replacement Leu by Val in the leader sequence whereas the 2 others are "silent". Intron 1 untranscribed region is presented in lower case. "*" indicates identity.
  • Figure 3 shows the cDNA nucleotide sequences of the variable heavy chain region of the rat anti-porcine xenograft monoclonal antibodies designated HA75DBF1 and IH21H7 aligned to demonstrate sequence homology. "*" indicates identity.
  • Figure 4 shows the cDNA nucleotide sequence of the variable heavy chain segment of the rat anti-pig xenograft monoclonal antibody designated HA75DBF1 aligned with its germ-line counterpart V ⁇ RAP.la obtained by genomic amplification of newborn LEW rat liver DNA. The two sequences are 98.6% (286/290) homologous.
  • HA75DBF1 cDNA differs at three nucleotides from the germ-line sequence. All three of these differences occur in the framework regions and are indicated by a box. "1" indicates identity.
  • organ transplants for the treatment of end- stage diseases has become an established and highly effective therapeutic regimen.
  • the success of organ transplantation has resulted in a shortage of human donor organs creating a major limitation to the more widespread use of this technology.
  • One of the practical solutions to the shortage of human donors is the use of species other than humans for organ donation. Even if only on a short-term basis, such organs could provide temporary life-support until a more suitable organ became available.
  • xenogeneic transplant results in a rejection reaction that is more aggressive than that observed for the transplantation of tissue between members of the same species (“allogeneic transplant”) .
  • the present invention provides novel and powerful immunological compositions and methods for inhibiting the antibody-mediated component of the rejection of xenografts.
  • pre-transplant treatment of the xenograft with these immunological compositions preferably supplemented by post- transplant therapeutic treatment of the xenograft recipient with these immunological compositions, prolonged survival of the graft can be achieved, providing the first, critical step to long-term xenograft survival.
  • This ability to intervene in the immune response opens the door to the use of xenografts as a meaningful alternative to the shortage of available allogeneic organs.
  • This invention also provided, for the first time, monoclonal antibodies that immunoreact with antigen expressed by endothelial cells of donor xenografts and which are capable of inducing antibody-mediated rejection of the xenograft.
  • monoclonal antibodies as well as the polypeptides from which they are formed and the polynucleotides which encode them, are valuable tools in the hands of researches who seek to better understand the xenogeneic rejection reaction and to devise new compositions and methods to overcome it, but whose efforts have been frustrated by the lack of available and reliable reagents with which to conduct their work.
  • compositions of the present invention are methods of using the compositions of the present invention to isolate and further characterize the antigen(s) responsible for precipitating xenogeneic transplant rejection.
  • anti-donor xenograft antibody that is immunoreactive with antigen expressed by endothelial cells of a xenograft from a donor animal and that are capable of inducing antibody-mediated rejection of the xenograft by a recipient animal.
  • the terms “isolated,” “substantially pure, “ or “recombinant” in their various grammatical forms as a modifier of proteins including antibodies and antibody materials, polypeptides, amino acid sequences, polynucleotides, and nucleic acid sequences or molecules means that the proteins, polypeptides, amino acid sequences, polynucleotides, and nucleic acid sequences or molecules so designated have been produced in such form by the hand of man, and thus are separated from their native in vivo cellular environment.
  • the isolated, pure and/or recombinant, proteins, polypeptides, amino acid sequences, polynucleotides, and nucleic acid sequences or molecules of the invention can be produced in large quantities and are useful in ways that the proteins, polypeptides, amino acid sequences, polynucleotides, and nucleic acid sequences or molecules as they naturally occur are not.
  • antibody and “antibody molecule” in their various grammatical forms are used herein as collective nouns to refer to a population of immunoglobulin molecules which may be polyclonal or, more preferably, monoclonal in origin and which may be of any isotype, preferably of the IgM isotype.
  • immunosorbent in its various grammatical forms means specific binding between an antigenic determinant- containing molecule, such as an antigen, and a molecule containing an antibody combining site such as an antibody molecule or antibody material .
  • xenograft refers to grafted tissue or tissue intended for use in a transplant operation between animals, including humans, that has been derived from a donor animal that is a different species than that of the recipient animal or intended recipient animal of the tissue. Typically, the tissue is organized in the form of a critical body organ.
  • xenografts suitable for use in the present invention are well-known in the art, such as kidney, heart, liver, lung, pancreas, and the like.
  • donor animal is a collective noun referring to the species of animal from which the xenograft is taken for transplant and can include, for example, domesticated animals such as pigs, non-human primates such as baboons, rodents such as hamsters and rabbits, and the like. Accordingly, the xenograft, being tissue of the donor animal, may be further designated herein by the type (species) of donor animal from which the xenograft originates, e.g. hamster xenograft.
  • recipient animal is used herein as a collective noun referring to the species of animal which receives the xenograft and includes, for example, humans, domesticated animals, primates, rodents, and the like.
  • antibody-mediated rejection of the xenograft refers to an immunological attack on the xenograft which is driven by humoral, as opposed to cell specific immunity, and which is thus mediated by antibody molecules.
  • Antibody-mediated rejection of a xenograft can be accelerated or hyperacute.
  • anti-donor xenograft antibody of the present invention is capable of inducing hyperacute rejection of the xenograft.
  • Anti-donor xenograft antibodies of either monoclonal or polyclonal form can be produced using techniques presently known in the art.
  • polyclonal and monoclonal antibodies can be produced as described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual (Cold
  • Altered antibodies such as chimeric, humanized, CDR-grafted or bifunctional antibodies can also be produced by methods well known to those skilled in the art. Such antibodies can also be produced by hybridoma, chemical or recombinant methodology described, for example in Ausubel et al. , Current Protocols in Molecular Biology (Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. 1993), also incorporated herein by reference. Exemplary methods of making and isolating monoclonal anti- donor xenograft antibodies are provided in EXAMPLES below.
  • polyclonal antibody in its various grammatical forms refers to a population of antibody molecules that contains more than one species of idiotope capable of immunoreacting with epitopes on a particular antigen.
  • Polyclonal antibody of the present invention specifically includes a mixture of more than one monoclonal antibody that immunoreact with different epitopes on the same antigen.
  • monoclonal antibody in its various grammatical forms refers to a population of antibody molecules that contain only one species of idiotope capable of immunoreacting with a particular epitope on an antigen.
  • a monoclonal antibody typically displays a single binding affinity for an epitope with which it immunoreacts; however, a monoclonal antibody may be a molecule having a plurality of idiotopes, each immunospecific for a different epitope, e.g., a bispecific monoclonal antibody.
  • Monoclonal antibodies are typically composed of antibodies produced by clones of a single cell called a hybridoma that secretes (produces) but one kind of antibody molecule.
  • hybridomas capable of producing antibodies and antibody materials having specific immunoreactivity with antigen expressed by endothelial cells of a xenograft from a donor animal is provided and described in greater detail below.
  • the hybridomas disclosed herein can be used to produce other immortal cell lines that produce antibody and antibody material of the present invention.
  • a hybridoma cell is formed by fusing an antibody- producing cell and a myeloma or other self-perpetuating cell line. The preparation of such hybridomas was first described by Kohler and Milstein, Nature. 256:495-497
  • an animal can either be transplanted with a xenograft from a donor animal or inoculated with a xenogeneic immunogen. If the transplant technique is used, preferably, the animal receiving the transplant is of the same species as the recipient animal.
  • xenogeneic immunogen in its various grammatical forms is used herein to describe a composition containing donor endothelial cell antigen as an active ingredient used for the preparation of the antibodies against antigen expressed by endothelial cells of a xenograft from a donor animal.
  • the amount of immunogen used to inoculate the mammal should be sufficient to induce an immune response to the immunizing antigen. This amount depends, among other things, on the species of animal inoculated, the body weight of the animal, the source and form of the donor endothelium antigen in the immunogen, and the chosen inoculation regimen as is well known in the art.
  • Antibody-producing cells e.g.
  • splenic lymphocytes are harvested from the immunized animal, or the transplanted animal after rejection of the xenograft, and can be fused with myeloma cells using polyethylene glycol ("PEG”) .
  • PEG polyethylene glycol
  • Fused hybrids are selected by their sensitivity to hypoxanthine, aminopterin and thymidine selection medium (“HAT”) .
  • a monoclonal antibody of the present invention can also be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes anti-donor xenograft antibody molecules.
  • the culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium.
  • the antibody-containing medium is then collected.
  • the antibody molecules can then be further isolated by well known techniques.
  • Other methods of producing a monoclonal antibody, a hybridoma cell, or a hybridoma cell culture are also well known. See, for example, the method of isolating monoclonal antibodies from an immunological repertoire as described by Sastry et al., Proc. Natl. Acad.
  • Anti-donor xenograft antibody can be identified by screening for the presence of antibody molecules that immunoreact with antigen expressed by endothelial cells of the donor animal and which are capable of inducing antibody- mediated rejection of the xenograft. Screening methods for such immunoreactivity can take any one of several commonly used immunoassay formats, including for example, radioimmunoassay (RIA) , enzyme linked immunosorbent assay (ELISA) or immunofluorescent assay.
  • RIA radioimmunoassay
  • ELISA enzyme linked immunosorbent assay
  • immunofluorescent assay The source of antigen in these immunoassays is endothelial cells or endothelial cell-containing tissue sections from a donor animal.
  • the source of antigen for the immunoassay is endothelial cells or endothelial cell-containing tissue sections from the same type of tissue as the xenograft and, most preferably, from the same individual animal that donates the xenograft.
  • An antibody is considered to "immunoreact with antigen expressed by endothelial cells of the donor animal" when binding by the test antibody exceeds binding detected in the negative control by at least about two times, preferably by at least about 2.5 times, and even more preferably by about three times, particularly when flow cytometric assay is employed.
  • the negative control for such assays is PBS or more preferably autologous serum.
  • a presently preferred method for screening for immunoreactivity is described with greater detail in the flow cytometry assay provided in the EXAMPLES below.
  • Screening methods to identify antibodies having the ability to induce antibody-mediated rejection of the xenograft include in vi tro cytotoxicity assays such as or example, flow cytometric cytotoxicity assay or MTT cytotoxicity assay, and in vivo rejection experiments using animal models.
  • vi tro cytotoxicity assays such as or example, flow cytometric cytotoxicity assay or MTT cytotoxicity assay
  • MTT cytotoxicity assay in vivo rejection experiments using animal models.
  • antibody-mediated, complement-dependent cytotoxicity indicates that antibody tested has the ability to mediate rejection of the donor xenograft by the recipient animal.
  • the source of antigen for the cytotoxicity assays can be as described above for the immunoreactivity assays, or other whole cells from the donor animal can be used.
  • the source of complement is animal serum which produces low background, e.g. Low ToxTM rabbit or mouse serum (Cedar Lane Laboratories, Hornby Ontario, Canada) .
  • antibody is capable of inducing antibody-mediated rejection of a xenograft by a recipient animal when more than about 20% cell death is detected.
  • a presently preferred flow cytometric cytotoxicity assay for detecting the ability of antibody to induce antibody-mediated rejection of a xenograft by a recipient animal is described with greater detail in the EXAMPLES below. One of skill in the art will appreciate that the assay described in Examples can easily be adapted for specie combinations of interest.
  • in vivo rejection experiments can be employed, where appropriate, to detect the capability of antibody to induce antibody-mediated rejection of a xenograft by a recipient animal.
  • the median survival times of a xenograft for the recipient animal must be characterized, preferably, the mean rejection time of a xenograft following pre-transplant passive transfer of hyperimmune serum to a recipient animal is also determined.
  • a recipient animal then receives by passive transfer an inoculation of the putative antibody. The quantity of inoculum depends on the several factors such as the type and weight of the recipient animal. Transplant of the xenograft is performed on the pre-treated recipient and xenograft survival time is determined.
  • An antibody is capable of inducing antibody-mediated rejection of the xenograft by the recipient if pre-transplant, passive transfer of the antibody results in accelerated, or more preferably hyperacute, rejection of a subsequently transplanted xenograft. Histological examination of the rejected xenograft can be performed to confirm that the rejection was antibody-mediated.
  • Naive LEW rats received passive transfer of hyperimmune rat serum by intravenous injection of about 0.1 to 0.5 ml sera. Rejection was considered to have occurred when the xenogeneic heart stopped beating.
  • Hyperimmune serum refers to sera from an animal that has rejected a xenograft originating from the donor animal.
  • the hyperimmune serum is from the same species of animal as the recipient animal on which the in vivo rejection experiment is to be performed.
  • Hyperimmune serum may be further designated herein by the animal from which it was derived, e.g., hyperimmune "rat” serum.
  • Total IgM levels at about Day 4 post-transplant were ⁇ 2.4 mg/ml as quantified by immunoprecipitation and compared to standards. This rise in total IgM was paralleled by a rapid rise in the rat recipient serum of IgM antibody that reacts exclusively with the vascular endothelium of normal hamster hearts and normal hamster splenic lymphocytes.
  • IgM producing B-cells from the spleen of rats that had received hamster heart transplants were used to generate antibodies of the present invention.
  • Rat hybridomas were produced by fusing rat myeloma cells (YB2/0) with splenic lymphocytes from LEW rat recipients of hamster cardiac xenografts. (See, EXAMPLES below.) The hybridomas were screened for IgM antibody production in an ELISA format as described in the EXAMPLES below. Antibodies from IgM- producing hybridomas were screened, using the immunofluorescent assay described in the EXAMPLES, for immunoreactivity to hamster endothelial antigens.
  • hyperacute rejection refers to the rejection of a xenograft in less than about one hour.
  • hybridomas were created which produce anti- donor xenograft antibodies, or more specifically, rat anti- hamster xenograft monoclonal antibodies, including four hybridoma cell lines stored in liquid nitrogen by Dr. Donald Cramer in suite 25ON of the Transplant Biology Research Laboratory of Cedars-Sinai Medical Center, located at 150 North Robertson Blvd., Beverly Hills, California, 90211. These three hybridoma cell lines are labeled and identified by the following laboratory names: HAR-1, ID12BF3, ID12CF2, and FC2EG11.
  • rat anti-hamster xenograft monoclonal antibodies demonstrated binding to hamster endothelium derived from various tissue sources including such vascularized organs as the heart, kidney, gut, liver, lung, brain, and tongue, and more specifically including arterial and capillary endothelial cells, lymphatic endothelium, intestinal epithelium, thymic epithelium and aortic endothelium in tissue sections.
  • the target antigen(s) are also associated with the reticular cells and macrophages of the splenic red pulp, the periarterial lymphoid sheath, and the thymic medullary epithelium.
  • Rat anti-hamster xenograft monoclonal antibodies also demonstrated a clear ability to induce antibody-mediated rejection of the xenograft by naive LEW rats. For example, when a one milliliter aliquot of culture supernatant from
  • HAR-1 was passively transferred pre-transplant to naive LEW rats, the mean rejection time of the subsequent hamster
  • xenografts was 10 minutes (Table 2, Group "HAR-1" ) .
  • HAR-1 hyperacute and is mediated by binding to endothelial antigen, as was the rejections
  • Naive rats receiving hamster cardiac xenografts and which are not subjected to pre- transplant treatment with HAR-1 have a mean rejection time of 3.9 days (Table 1, "Hamster --> LEW rat") .
  • the mean graft rejection time induced by pre-transplant treatment of naive rats with culture supernatant from a hybridoma producing IgM monoclonal antibody that lacked binding specificity for endothelium (Table 2, "9D6”) was four days, the time to rejection normally seen in naive rats.
  • the hyperacute rejection precipitated by HAR-1 was slightly more severe, but comparable to, the hyperacute rejection precipitated by pre-transplant treatment of naive rats with serum from a transplanted rat. (Table 2, Group "Poly”) .
  • HAR-1 binding specificity was further characterized in terms of its inability to bind tissue other than hamster endothelium.
  • Flow cytometric analysis and hemagglutination assays of HAR-1 demonstrates limited binding of the antibody to erythrocytes or splenic lymphocytes.
  • HAR-1 reacts specifically with vascular endothelium, triggering complement activation and intravascular thrombosis heart xenografts.
  • the binding of the rat anti-donor xenograft monoclonal antibodies and the activation of complement with subsequent intravascular thrombosis are the same lesions as those seen in models of hyperacute rejection due to passive transfer of hyperimmune serum.
  • anti-hamster xenograft antibody characterized as immunoreactive with antigen expressed by endothelial cells of a hamster xenograft and capable of inducing antibody-mediated rejection of the hamster xenograft by a recipient animal.
  • the hamster xenograft is heart tissue or the recipient animal is a rat. More preferable the hamster xenograft is heart tissue and the recipient animal is a rat.
  • such antibodies may be of any isotype, preferably they are of the IgM isotype and bind proteins producing 40 kDa and 80 kDa bands by Western blot analysis.
  • the isolated and substantially purified anti-hamster xenograft antibody is further characterized as comprising at least one polypeptide encoded by a nucleic acid sequence which includes a sequence having at least about 90% homology, preferably at least about 95% homology, more preferably at least about 98% homology, and most preferred about 100% homology to the sequence defined by nucleic acid residues 58 through 351 of SEQ ID NO: 1 or nucleic acid residues 168 through 440 of SEQ ID NO: 9.
  • compositions which have amino acid residue sequence substantially identical to a sequence specifically shown herein merely by making conservative substitutions in one or more residues of the sequence with a functionally similar residue and which displays the ability to mimic the compositions as described herein.
  • conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar
  • hydrophilic residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.
  • “Chemical derivative” refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group.
  • Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups.
  • Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides.
  • Free hydroxyl groups may be derivatized to form 0-acyl or 0-alkyl derivatives.
  • the imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine.
  • chemical derivatives those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.
  • Polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions of residues relative to the sequence of a polypeptide whose sequence is shown herein, so long as the requisite activity is maintained.
  • the antibody is characterized as being immunoreactive with antigen expressed by endothelial cells of a hamster xenograft, capable of inducing antibody-mediated rejection of the hamster xenograft by a recipient animal and comprising at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by nucleic acid residues 58 through 420 of SEQ ID NO: 1 or by a nucleic acid sequence including the sequence defined by nucleic acid residues 1 through 354 of SEQ ID NO: 3.
  • the anti-hamster xenograft antibody further comprises at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by SEQ ID NO: 5.
  • PAEC pig aortic endothelial cells
  • the antibodies that appear to be most closely associated with the xenograft reaction are of the IgM isotype, although IgG and IgA antibodies have reported to be involved in the rejection of pig tissue by humans.
  • the cytotoxic activity of human preformed antibodies to pig endothelium is most clearly the result of the binding of IgM and not IgG antibodies.
  • rat anti-porcine xenograft monoclonal antibodies were generated using traditional hybridoma techniques as described in the EXAMPLES below and in Yokayama, W.M. , Current Protocols in Immunology. Colifan, J, et al.
  • LEW rats were immunized with PAEC and splenic lymphocytes of the rat were harvested and fused with rat YB2/0 myeloma cells to produce hybridomas.
  • Antibodies secreted by these hybridomas were then subjected to several assays including assays which identified antibodies which are immunoreactive with antigen expressed by endothelial cells of a xenograft from a donor animal and which are capable of inducing antibody-mediated rejection of the xenograft by a recipient animal.
  • PAEC immunoreactivity was determined in an ELISA format as described in the EXAMPLES below using PBS and pig serum as negative controls.
  • Another selection criterion which is presently prefered is the ability of the rat anti-porcine xenograft monoclonal antibodies to immunoreact antigen expressed by pig platelets as is characteristically observed with preformed human anti- porcine xenograft antibodies.
  • the panel of 83 rat anti-porcine xenograft monoclonal antibodies were tested for their ability to immunoreact with pig platelets. Most of these monoclonal antibodies tested positive. These results were confirmed in an ELISA assay using pig platelets as targets and human serum as a positive control.
  • IgM anti-porcine xenograft antibody
  • the isotypes of the monoclonal antibodies were determined in an ELISA format as described in the EXAMPLES below. Twelve of the 83 hybridomas having immunoreactivity for PAEC secrete antibody of the IgG isotype, and the remainder are IgM.
  • Anti-porcine xenograft monoclonal antibodies were identified amongst the 83 monoclonal antibodies which demostrated immunoreactivity with antigen expressed by PAEC by their ability to induce antibody-mediated rejection of the xenograft by a recipient animal.
  • these 83 monoclonal antibodies were their ability to kill PAEC in a complement-mediated flow cytometric cytoxicity assay as described in the EXAMPLES below.
  • Eleven anti-porcine xenograft monoclonal antibodies identified each being highly cytotoxic (>80%) to PAEC in the complement-mediated cytotoxicity assays. The results were identical when purified rabbit complement or rat serum was used as a source of complement. Autologous complement, as expected, was not cytotoxic for PAEC.
  • Hybridoma cell lines secreting these anti-porcine xenograft antibodies are stored in liquid nitrogen by Dr.
  • the present invention thus includes isolated and substantially purified anti-donor xenograft antibody ("anti- porcine xenograft antibody”) characterized as being immunoreactive with antigen expressed by endothelial cells of a pig xenograft and capable of inducing antibody-mediated rejection of the pig xenograft by a recipient animal.
  • anti-donor xenograft antibody anti- porcine xenograft antibody
  • the pig xenograft is heart tissue or liver tissue.
  • the recipient animal is a human.
  • the anti-porcine xenograft antibodies of the present invention are of the IgM isotype. Even more preferably, the anti-porcine xenograft antibodies of the present invention immunoreact with antigen expressed by pig platelet cells.
  • the isolated and substantially purified anti-porcine xenograft antibody is further characterized as comprising at least one polypeptide encoded by a nucleic acid sequence which includes a sequence having at least about 90% homology, preferably at least about 95% homology, more preferably at least about 98% homology, and most preferred about 100% homology to the sequence defined by nucleic acid residues 1 through 291 of SEQ ID NO: 18 or nucleic acid residues 1 through 291 of SEQ ID NO: 20.
  • the antibody is characterized as being immunoreactive with antigen expressed by endothelial cells of a pig xenograft, capable of inducing antibody-mediated rejection of the pig xenograft by a recipient animal and comprising at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by nucleic acid residues 1 through 345 of SEQ ID NO: 18 or defined by nucleic acid residues 1 through 357 of SEQ ID NO: 20.
  • Another selection criterion for presently prefered anti-porcine xenograft antibody is complement-mediated cytotoxicity for pig spleen lymphocytes.
  • anti-porcine xenograft monoclonal antibodies were screened for cytotoxicity to pig splenic lymphocytes. All eleven monoclonal antibodies also have the capacity to bind and induce complement-mediated splenic lymphocytes cell death; findings which are characteristic of many preformed human anti-porcine xenograft antibodies.
  • anti-porcine xenograft antibodies of the present invention preferably are also capable of inducing complement-mediated death of pig spleenic lymphocytes.
  • Still another selection criterion for presently prefered anti-porcine xenograft antibody is immunoreactivity with proteins having molecular weights similar to those which bind with preformed human anti-porcine xenograft antibodies.
  • immunoprecipitation of 125 I labeled PAEC surface antigens it was demonstrated that several of the monoclonal antibodies immunoprecipitate proteins of about the same molecular weight as antigens expressed by PAEC or pig platelet cells and which are recognized by preformed human anti-porcine xenograft antibodies.
  • Preformed human anti-porcine xenograft antibodies bind at least six antigens expressed by pig aortic endothelial cells with molecular weights of 44 kDa, 80 kDa, 115kDa, 125 kDa, 135 kda and 200 kDa by Western blot analysis. Three antigens of similar molecular weights (115kD, 125kD, and 135kD) which are expressed on pig platelet cells are also bound by these preformed human anti-porcine xenograft antibodies.
  • the anti-porcine xenograft antibodies of the present invention be immunoreactive with at least one antigen expressed by pig endothelial cells or pig platelet cells which are also recognized by preformed human anti-porcine xenograft antibodies. Even more preferably, the anti-porcine xenograft antibodies of the present invention are also capable of blocking preformed human anti-porcine xenograft antibody from binding to PAEC or LCPK1 pig kidney cells.
  • LCPK1 cells are included in these screening assays because it has been reported that they express the 115 kDa molecule recognized by preformed human anti-porcine IgG antibodies and express ⁇ Gal terminal residues on surface antigens that are targets of preformed human anti-porcine antibody binding and cytotoxicity. See, Koren, E. et al. , "Cytotoxic effects of human preformed anti-gal IgG and complement on cultured pig cells.” Second Intern'1 Congress on Xenotransplantation.
  • the anti-porcine xenograft antibodies described above were screened for their ability to block preformed human anti-porcine xenograft antibody (as they occur in normal human serum) from binding to PAEC or LCPK1 pig kidney cells. These blocking studies were performed with groups of anti- porcine xenograft monoclonal antibodies in order to screen larger numbers of monoclonal antibodies more efficiently. Each group, comprising four to five individual monoclonal antibodies, was incubated with PAEC or LCPK1 cells. The cells were then incubated with human serum as a source of preformed human anti-porcine xenograft antibodies.
  • Anti- porcine xenograft monoclonal antibodies in Group 1 were capable of reproducibly blocking 50-65% of preformed human IgM anti- porcine xenograft antibody binding to LCPK1 cells as indicated by a drop in mean channel shift from 242.5 with human serum alone to 59.9 following preincubation with Group 1 monoclonal antibodies.
  • Group 1 anti-porcine xenograft antibodies were also capable of blocking binding of prefomed human anti-porcine xenograft antibodies to PAEC, indicated by a drop in mean channel shift from 73.6 with human serum alone to 47.2 following preincubation with Group 1 monoclonal antibodies.
  • the rat anti-porcine xenograft monoclonal antibodies in Group 2 did not significantly block preformed human IgM anti-porcine xenograft antibody binding to pig cells (mean channel shift of 219.2) in the same experiment but demonstrated an equivalent level of binding to LCPK1 cells as Group 1.
  • anti-donor xenograft antibody material characterized as immunoreactive with antigen expressed by endothelial cells of a donor xenograft and capable of inhibiting antibody-mediated rejection of the donor xenograft by a recipient animal.
  • antibody material in its various grammatical forms is used herein as a collective noun that refers to a population of immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain an antibody combining site.
  • Exemplary antibody materials of the present invention include those portions of immunoglobulin molecules known in the art as Fab, Fab', F(ab') 2 / and F (v) .
  • Fab and F(ab') 2 portions of antibodies are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by methods that are well known. See, for example, U.S. Patent No. 4,342,566 to Theofilopolous and Dixon.
  • Fab' antibody portions are also well known and are produced from F(ab') 2 portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide.
  • An antibody combining site is that structural portion of the antibody molecule comprised of a heavy and light chain variable and hypervariable regions that specifically binds (immunoreacts with) an antigen.
  • anti-donor xenograft antibody material refers to antibody material that immunoreacts with antigen expressed by endothelial cells of a xenograft and that inhibits antibody-mediated rejection of the xenograft by the recipient animal.
  • anti-donor xenograft antibody material is selected from the group consisting of Fab, Fab 1 , F(ab') 2 , F(v) and combinations of thereof.
  • anti-donor xenograft antibody material is selected from the group consisting of F(ab') 2 and Fab' .
  • anti- donor xenograft antibody material is comprises a combination of F(ab' ) 2 and Fab' .
  • anti-donor xenograft antibody can simply be reduced into fragments that retain their ability to immunoreact with antigen expressed by endothelial cells of the xenograft but that are incapable of inducing complement-mediated death of xenograft cells.
  • more sophisticated methods such as the phage display technique (descibed in greater detail below) can be used to generate anti-donor xenograft antibody material of the present invention.
  • Screening antibody material for immunoreactivity with antigen expressed by endothelial cells of the xenograft is similar to the method of screening antibodies for the same attribute as described above and in the EXAMPLES, except that an appropriate secondary antibody should be substituted, such as for example enzyme-labeled anti-kappa antibody.
  • an appropriate secondary antibody such as for example enzyme-labeled anti-kappa antibody.
  • the inability to induce antibody-mediated, complement-dependent cytotoxicity indicates that that antibody tested has the ability to inhibit antibody-mediated rejection of the donor xenograft by the recipient animal.
  • the source of antigen and complement for the cytotoxicity assays can be as described above for the immunoreactivity assays, or other whole cells from the donor animal can be used as a source of antigen.
  • antibody is capable of inhibiting antibody-mediated rejection of a xenograft by a recipient animal when cell death is reduced by at least about 20% as compared to a control, preferably by at about 25% as compared to a control, more preferably by at least about 30% as compared to a control, even more preferably by at least about 35% and most preferably by at least about 40%.
  • flow cytometric cytotoxicity assay described in EXAMPLES can easily be adapted for specie combinations of interest.
  • the ability of anti-donor xenograph antibody material to inhibit antibody- mediated rejection of the xenograft is detected by the ability of the antibody material to block binding of preformed anti-donor xenograph antibodies in the recipient animal serum to antigen expressed by endothelial cells of the xenograft.
  • the ability of anti-porcine xenograft antibodies to block such binding can be screened for in the ELISA format or the flow cytometric assay described in the EXAMPLES below.
  • the ability to inhibit antibody-mediated rejection of the xenograft is detected by the ability of the antibody material to block at least about 20% of the binding detected with normal recipient serum, more preferably at least about 30% of the binding detected with normal recipient serum, even more preferably at least about 30% of the binding detected with normal recipient serum, and most preferably at least about 50% of the binding detected with normal recipient serum.
  • the ability of the antibody material to inhibit antibody-mediated rejection of a donor xenograft is identified in the in vivo rejections experiments described above when pre-transplant passive transfer of anti-donor xenograft antibody material prolongs the median survival time of the xenograft beyond the median survival time characteristic of the hyperacute rejection of a xenograft by the recipient animal, or more preferably beyond the median survival time of the xenograft characteristic of the accelerated rejection of a xenograft by the recipient animal.
  • post-transplant passive transfer of hyperimmune sera or anti-donor xenograft antibody of the present invention is administered to the transplant recipient in such in vivo experiments to generate the characteristic hyperacute rejection of the xenograft, such as is exemplified in the following hamster-to-rat model.
  • rat anti-donor xenograft monoclonal antibodies of the present invention have specificity for vascular endothelium of hamsters and could induce the hyperacute rejection reaction through activation of the classic complement pathway
  • rat anti-hamster xenograft antibodies were reduced to antibody material and screened for their ability to inhibit antibody-mediated rejection of the xenograft by rats.
  • naive rats received pre-transplant treatment of a single passive transfer of 0.5 ml rat hyperimmune sera.
  • group 2 referred to as the "HAR-1 group
  • the naive rats received pre-transplant treatment of 1.0 ml of HAR-1 (50-100 ⁇ g/protein) in a single passive transfer.
  • group 3 referred to as “HAR-l red /Poly group”
  • the naive rats received pre-transplant treatment of 1.0 ml HAR-1 Fab and F(ab) 2 antibody material, followed by passive transfer of 0.5 ml rat hyperimmune sera.
  • Group 4 referred to as "HAR-l red /HAR-l group” received pre-transplant treatment of 1.0 ml HAR-1 Fab and F(ab) 2 antibody material, followed by passive transfer of 1.0 ml HAR-1.
  • HAR-1 has specificity for the xenoantigen(s) which are primarily responsible for generating antibody-mediated hyperacute rejection and that are also recognized by the antibodies of transplanted rat sera; and (2) the usage of anti-donor xenograft antibody material (e.g., Fab, F(ab) 2 ) can inhibit antibody-mediated xenograft hyperacute rejection.
  • anti-donor xenograft antibody material e.g., Fab, F(ab) 2
  • anti-hamster xenograft antibody material which is characterized as immunoreactive with antigen expressed by endothelial cells of a hamster xenograft and capable of inhibiting antibody-mediated rejection of the hamster xenograft by a recipient animal.
  • the hamster xenograft is heart tissue or the recipient animal is a rat. More preferable the hamster xenograft is heart tissue and the recipient animal is a rat .
  • the isolated and substantially purified anti-hamster xenograft antibody material is further characterized as comprising at least one polypeptide encoded by a nucleic acid sequence which includes a sequence having at least about 90% homology, preferably at least about 95% homology, more preferably at least about 98% homology, and most preferred about 100% homology to the sequence defined by nucleic acid residues 58 through 351 of SEQ ID NO: 1 or by nucleic acid residues 168 through 440 of SEQ ID NO: 9.
  • the antibody material is characterized as being immunoreactive with antigen expressed by endothelial cells of a hamster xenograft, capable of inhibiting antibody-mediated rejection of the hamster xenograft by a recipient animal and comprising at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by nucleic acid residues 58 through 420 of SEQ ID NO: 1 or by a nucleic acid sequence including the sequence defined by nucleic acid residues 1 through 354 of SEQ ID NO: 3.
  • the anti-hamster xenograft antibody further comprises at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by SEQ ID NO: 5.
  • isolated and substantially purified anti- donor xenograft antibody material (“anti-porcine xenograft antibody material") characterized as being immunoreactive with antigen expressed by endothelial cells of a pig xenograft and capable of inhibiting antibody-mediated rejection of the pig xenograft by a recipient animal.
  • the pig xenograft is heart tissue or liver tissue.
  • the recipient animal is a human.
  • the isolated and substantially purified anti-porcine xenograft antibody material is further characterized as comprising at least one polypeptide encoded by a nucleic acid sequence which includes a sequence having at least about 90% homology, preferably at least about 95% homology, more preferably at least about 98% homology, and most preferred about 100% homology to the sequence defined by nucleic acid residues 1 through 291 of SEQ ID NO: 18 or by nucleic acid residues 1 through 291 of SEQ ID NO: 20.
  • the antibody material is characterized as being immunoreactive with antigen expressed by endothelial cells of a pig xenograft, capable of inhibiting antibody-mediated rejection of the pig xenograft by a recipient animal and comprising at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by nucleic acid residues 58 through 345 of SEQ ID NO: 18 or defined by nucleic acid residues 1 through 357 of SEQ ID NO: 20.
  • Anti-donor Xenograft Monoclonal Antibodies Show Sequence Homology to One Another and to Germline Sequences
  • a surprising and unexpected attribute of the anti-donor xenograft antibody material of the present invention is that anti-donor xenograft antibody material could inhibit antibody-mediated rejection of a xenograft and that polyclonal anti-donor xenograft antibody material was not required.
  • This result suggest that the preformed anti-donor xenograft antibodies responsible for mediating xenograft rejection are polyreactive. Without being bound by any particular theory, it is presently believed that hyperacute rejection of xenografts is mediated by preformed polyreactive anti-donor xenograft antibodies having V H germline configurations.
  • Immunoglobulin heavy and light chain cDNA libraries were constructed from mRNA of hybridomas producing rat anti- xenograft monoclonal antibodies.
  • the PCR technique was employed with primers for the proximal part of the constant region of the heavy ( ⁇ ) or light (K and ⁇ ) chain to synthesize a first strand cDNA from mRNA isolated from the HAR-1-producing the hybridoma and the ID12BF3-producing hybridoma.
  • a double-stranded synthetic linker of known sequence was ligated to the 5 ' end of the cDNA to facilitate the amplification of all V, D, and J genes rearranged to the constant region.
  • the cDNA was amplified by PCR using a second upstream constant region primer and the sense strand of the linker.
  • the amplified product was cloned into the pCR ® vector of the TA cloning kit ® (Invitrogen, San Diego, CA) to establish the library.
  • Recombinant clones were screened directly from bacterial colonies by PCR and their nucleic acid sequences characterized. This method was found to be more powerful and practical to use than anchored PCR, which utilizes the addition of a 3 ' tail to the first strand cDNA to clone sequences with unknown 5 ' ends.
  • the HAR-1 cDNA sequence of the heavy chain variable region is shown in SEQ ID NO. 1 and Figure 1.
  • the ID12BF3 cDNA sequence of the heavy chain variable region is shown in SEQ ID NO. 3.
  • the V H segments of these two rat anti-hamster xenograft monoclonal antibodies which were generated in separate by fusions are nearly identical to one another.
  • sequence of this V H segment alone was compared to sequences available on GeneBank ® , three rat sequences (Accession Nos. RRIGCD25H, RNIGHCAZ, and RNIGHNCS) were identified as having about 91% homology.
  • rat V H segments into different families and subfamilies are not yet available, however, using the criterion for membership in human V H gene families, the four rat V H gene sequences would belong to the same V H family.
  • Six mouse sequences were also found to have about 87% homology to the rat anti-hamster xenograft monoclonal antibody V H segment.
  • HAR-1 and ID12BF3 monoclonal antibodies were found to utilize different J H segments.
  • the cDNA sequence of the HAR-1 J H segment was found to be 98.2% homologous to the rat germline J H 1 gene: identical except for a substitution C for A in the first codon of germline J H 1.
  • the cDNA sequence of the ID12BF3 J H segment was found to be 100% homologous to the rat germline J H 2 gene. Due to possible N region and P element variations during the recombination process, it was not possible to clearly set the boundaries for D H segment of HAR-1 and ID12BF3, although it is evident that the D segments of these antibodies differ from one another. Nevertheless, a search was also conducted to identify any known sequences with greater that 70% homology to the totality of the cDNA sequence between the end of the V H segment and the beginning of the J H segment of HAR-1. No relevant match was found with any of the sequences of the Genebank ® database.
  • the nucleotide and deduced amino acid sequences of the variable region for HAR-1 kappa light chain were also used to search the GeneBank ® database for homologous sequences.
  • the nucleic acid sequence of the HAR-1 V ⁇ segment has about 90% sequence homology to three anti-DNA antibody V ⁇ segments which are all members of the V ⁇ 8 family defined in mice.
  • a germline counterpart for the HAR-1 V ⁇ segment has not yet been identified, but a search of the Genebank ® database has demonstrated that the J ⁇ segment of HAR-1 matches the first 36 nucleotides of the rat germline J ⁇ 2 (Genebank ® Accession No. RNIGKJCA) with 100% identity.
  • RVH1 and RVH2 respectively in Figure 1
  • HAR-1 and ID12BF3 Genomic sequence information was obtained from 3 individual clones.
  • H7RVH2 which anneals to the framework 3 region of the variable heavy chain
  • H7RVH3 which anneals upstream of the initiation codon of HA75D8F1
  • V H 1.1 Alignment of germline DNA (SEQ ID NO. 9 and referred to herein as V H 1.1) and cDNA sequences for the HAR-1 V H segment is shown in Figure 2. Three differences were found over a total of 376 nucleotides; the V H segment was 99% homologous to the germline sequence. One transversion C for G led to a replacement of leucine by valine in the eleventh amino acid position of the leader sequence. The two other differences, A for G at position 48 of framework region 1, and T for C at position one of framework region 2, were silent. Alignment of VH1.1 and the cDNA sequence for ID12BF3 also showed about 99% homology to VH1.1, but as a result of different nucleic acid substitutions.
  • VHRAP.la germline DNA
  • cDNA sequence for HA75DBF1 V H segment Alignment of germline DNA (referred to herein as VHRAP.la) and the cDNA sequence for HA75DBF1 V H segment is shown in Figure 4. Three differences were found over a total of 290 nucleotides; the V H segment was 98.6% homologous to the germline sequences . All three of these differences occur in the framework regions of the cDNA sequence of HA75D8F1.
  • the level of the sequence homology, the location of nucleic acid substitutions, and failure of these substitutions to significantly change the deduced amino acid sequence of the V H segment, provide further evidence that the hyperacute rejection of xenografts is mediated by polyreactive anti-donor xenograft antibodies having V H germline configurations.
  • the genetic characteristics were also determined for the 9D6 monoclonal antibody.
  • the cDNA sequence of the V H segment of 9D6 demonstrated a high percentage of identity with three members of the V H 4 family as defined in mice.
  • Comparison of heavy chain variable regions of HAR-1 and 9D6 demonstrated an overall homology of 77%.
  • CDRs complementarity determining regions
  • V H genes were constructed from splenic B lymphocytes of newborn rats, naive adult rats, rats which received hamster-xenografts at Day 4 post-transplant, and rats which received hamster- xenografts at Day 21 post-transplant, to establish which germline sequences was utilized for V H segments in vivo by the recipient animals.
  • the precursory frequency of the V H 1.1 germline sequence was established by dot hybridization of immunoglobulin specific gene libraries with primers specific for the V H 1.1 gene segment. See, J. Sambrook, et al . , Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, p.
  • V H 1.1 gene expression was 1.2% and 1.0% in the newborn and naive adult animals, respectively.
  • the gene frequency was increased to 16% in the recipients of hamster xenografts at Day 4 post-transplant and 10.3% in the recipients at Day 21 post-transplant.
  • the B cell subset (s) expressing the specific IgM V H gene utilized in mediating the primary humoral response of the rats to hamster xenografts exist at substantial levels in newborn and adult animals.
  • B cells undergo rapid clonal expansion and express the V H gene in a germline configuration after the challenge of rat recipients with hamster xenografts. Sequence analysis of clones from these libraries have demonstrated that the V H genes used in response to the hamster heart xenografts as well as the porcine xenografts are restricted to a small number of closely-related genes.
  • the basic features of the xenograft rejection despite the involvement of widely divergent species, represent a rather stereotypical and relatively primitive antibody response to endothelial antigens expressed by the graft .
  • the binding of these antibodies to similar antigens expressed by many different species may be central theme in the pathogenesis of the reaction and may provide the opportunity to specifically target critical steps in the rejection reaction.
  • the ability of a single monoclonal antibody to block the rejection of hamster heart xenografts by rat recipients is clear support for the concept that antibodies and/or their derived fragments will have a role in preventing the xenograft reaction in many species, including the pig-to-human combination.
  • the present invention also encompasses isolated and purified polynucleotide molecules encoding antibodies, antibody material, and polypeptide of the present invention. This invention also encompasses polynucleotide molecules characterized by conservative changes in coding regions that do not alter the phenotype of the polypeptide produced therefrom when compared to the nucleic acid molecule described herein.
  • This invention provides isolated and purified polynucleotides comprising a nucleic acid sequence encoding at least one of the following polypeptides: the polypeptide defined by amino acid residues 1 through 354 of SEQ ID NO: 2; the polypeptide defined by amino acid residues 1 through 402 of SEQ ID NO: 5; the polypeptide defined by amino acid residues 1 through 354 of SEQ ID NO: 3; the polypeptide defined by amino acid residues 1 through 345 of SEQ ID NO: 18; the polypeptide defined by amino acid residues 106 through 151 of SEQ ID NO: 20.
  • the present invention also provides isolated and purified polypeptides defined by these amino acid sequences.
  • polynucleotide refers to a contiguous sequence of DNA, RNA, or preferably cDNA.
  • polypeptide encompasses any naturally occurring allelic variant thereof as well as man-made recombinant forms.
  • the present invention specifically contemplates the use of the phage display technique in combination with PCR amplification of immunoglobulin heavy and light chain libraries as an alternative method of producing and screening for anti-donor xenograft antibody material of the present invention.
  • the phage display technique is particularly useful in producing and screening human anti-donor xenograft antibody material.
  • a preferred coat protein for use in this invention in providing a membrane anchor is cp III.
  • methods for operatively linking a nucleotide residue sequence encoding a heavy chain to cp III membrane anchor in a fusion protein of this invention are described.
  • a phagemid vector is selected that contains a single cistron consisting of an expression control sequences operatively linked to a periplasmic secretion signal (pelB leader) and a sequence encoding cpIII.
  • pelB leader a periplasmic secretion signal
  • cpIII provides a membrane anchor.
  • the phagemid expression vector suitable for production of the antibody material of the present invention should also carry a selectable resistance marker gene, a phage origin that allows the vector to be replicated as a single stranded DNA and subsequently packaged into phage particles and a bacterial origin of replication that allows the vector to be replicated in a suitable host as double-stranded DNA.
  • a presently prefered phagemid is the SurfZapTM Vector provided in a kit by Statagene, La Jolla, California.
  • the pelB leader sequence encodes a first restriction site at its 3 ' end and the cpIII sequence encodes a second restriction site at its 5' end.
  • restriction site allow nucleic acid sequences encoding immunoglobulin light and heavy chains to be inserted in the proper orientation as one continuous strand.
  • Expression of the cistronic message encoding the pelB- V ⁇ -V H -cp III fusion sequence leads to the formation of a continuous amino acid seqence that is delivered to the periplasmic space by the pelB leader sequence.
  • the pelB leader is subsequently cleaved and the V ⁇ - V H chain is anchored in the membrane by the cp III membrane anchor domain.
  • the heavy chain in the presence of the light chain assembles to form Fab molecules.
  • the coat protein III is incorporated on the tail of the bacteriophage thereby displaying the Fab on the exterior of the phage particle.
  • Phage particles diplaying the Fab can then be screened for binding to antigen expressed by endothelial cells of a xenograft by the panning method described in the EXAMPLES.
  • Positive phage can be amplified and large quantities of pure Fab produced by co- infection of phagmid and helper phage.
  • the phagemid immunoglobulin insert can also be sequenced either by isolation of the insert or directly from the phagemid.
  • the donor xenograft is donated by a pig, and more preferably, the pig xenograft is a pig heart or pig liver.
  • the human anti-donor xenograft antibody material described above further comprising at least one polypeptide encoded by a nucleic acid sequence including the sequence defined by nucleic acid residues 1 through 345 of SEQ ID NO: 18 or residuesl through 357 of SEQ ID NO: 20, and at least one human immunoglobulin light chain.
  • Such antibody materials can easily be generated by modification of the [hage display technique described herein to use these heavy chain sequences instead of the sequences obtained through amiplification of the human heavy chain genome.
  • polynucleotides and polypeptides encoding the antibodies and antibody materials of the present invention.
  • this invention provides recombinant anti-donor xenograft antibody material characterized as immunoreactive with antigen expressed by endothelial cells of a donor xenograft and capable of inhibiting antibody- mediated rejection of the donor xenograft by a recipient animal, wherein said antibody material comprises at least one immunoglobulin light chain polypeptide and at least one immunoglobulin heavy chain variable region polypeptide.
  • said immunoglobulin light chain polypeptide is human or the immunoglobulin heavy chain variable region polypeptide is human. Even more preferably, both polypeptides are human.
  • nucleic acid encoding these recombinant anti-donor xenograft antibody material is provided.
  • Such nucleic acids can be incorporated into vectors, such as for example phagemid vectors including the SurfZAP vector.
  • vector refers to a recombinant DNA molecule capable of autonomous replication in a cell and to which a DNA segment, e.g., gene or polynucleotide, can be operatively linked so as to bring about replication of the attached segment.
  • Vectors capable of directing the expression of genes and coding for one or more polypeptides are referred to herein as "expression vectors. "
  • This invention also provides a vector comprising an isolated nucleic acid molecule such as DNA, cDNA or RNA encoding anti-donor xenograft antibody material or the peptide componetns thereof.
  • additional vectors useful herein are viruses, such as bacteriophages, baculoviruses and retroviruses, cosmids, plasmids, and the like.
  • Nucleic acid molecules are inserted into vector genomes by methods well known in the art. For example, insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules that base pair with each other and which are then joined together with a ligase.
  • synthetic nucleic acid linkers that correspond to a restriction site in the vector DNA, can be ligated to the insert DNA which is then digested with a restriction enzyme that recognizes a particular nucleotide sequence.
  • an oligonucleotide containing a termination codon and an appropriate restriction site can be ligated for insertion into a vector containing, for example, some or all of the following: a selectable marker gene, such as neomycin gene for selection of stable or transient transfectants in mammalian cells, • enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColEl for proper episomal replication; versatile multiple cloning sites; and T7 and SP6 RNA promoters for in vi tro transcription of sense and antisense RNA.
  • Other means are available and can readily be accessed by those of skill in the art.
  • Cells transformed with vectors of the present invention are also provided, particularly including E. coli .
  • anti-donor xenograft antibody materials and anti- donor antibodies of the present invention can readily be used in the methods of the present invention.
  • novel methods of inhibiting antibody-mediated rejection of a xenograft from a donor animal by a recipient animal which comprises modifying antigen expressed by cells of the xenograft, without causing lysis of the cells, so as to inhibit specific binding of recipient anti-donor xenograft antibody to said antigen.
  • these antigens expressed by cells of the xenograft are capable of inducing an antibody-mediated immune response by the recipient animal which, if untreated, results in the rejection of the xenograft.
  • Antigen targeted for modification in accordance with the methods of the present invention are preferably expressed by endothelial cells of the donor xenograft.
  • rejection of a xenograft may involve several immunologic components each having varying degrees of importance as rejection of the xenograft proceeds to completion and is dependent upon the combination of species selected for the xenograft transplant.
  • An objective of the present invention is to disrupt the antibody-mediated (i.e., humoral as opposed to cell-mediated) component of the rejection by directly or indirectly modifying antigen presented by the xenograft in such a manner that immunoreactivity (specific binding) between antigen and recipient anti-donor xenograft antibody is reduced or eliminated.
  • the term "recipient anti-donor xenograft antibody” refers to antibody molecules produced by the individual recipient of the xenograft that immunoreact with, i.e., specifically bind, antigen expressed by the cells of the xenograft and induce antibody-mediated rejection of the donor xenograft. Accordingly, such antibodies may be further designated herein by the species of the individual recipient animal (e.g. human) producing the antibodies and/or the specific type of donor animal (e.g. porcine) from which the xenograft originates.
  • the species of the individual recipient animal e.g. human
  • the specific type of donor animal e.g. porcine
  • recipient anti-donor xenograft antibody produced by a human and having specificity for a xenograft from a pig may be refered to herein as human anti-porcine xenograft antibody.
  • Recipient anti-donor xenograft antibody include anti-donor xenograft antibody that naturally occur in the recipient prior to transplant of the xenograft (preforemd antibodies) and anti-donor xenograft antibodies naturally produced by the recipient after transplant of the xenograft.
  • modifying antigen expressed by cells of the xenograft comprises contacting non-lytic, anti-donor xenograft antibody material with the antigen for a time, at a temperature, and at a pH suitable to bind the antibody material to the antigen, wherein said anti-donor xenograft antibody material is characterized as immunoreactive with antigen expressed by endothelial cells of the xenograft and capable of inhibiting antibody-mediated rejection of the xenograft by a recipient animal.
  • non-lytic, anti-donor xenograft antibody material is derived from the same species of animal as the recipient animal.
  • nonlytic, anti- donor xenograft antibody material may be contacted with antigen prior to transplant, after transplant or both.
  • antigen expressed by cells of the xenograft may be modified by contacting the antibody material with the antigen by ex vivo perfusion of the xenograft with a solution comprising a preservative for the xenograft, such as for example, ViaspirTM (DuPont-Merck Pharmaceuticals, Co.) and the anti-donor xenograft antibody material for a time, at a temperature, and at a pH suitable to bind the antibody material to the antigen.
  • a preservative for the xenograft such as for example, ViaspirTM (DuPont-Merck Pharmaceuticals, Co.) and the anti-donor xenograft antibody material for a time, at a temperature, and at a pH suitable to bind the antibody material to the antigen.
  • binding of anti-donor xenograft antibody material with antigen expressed by cells of the xenograft can be acheived and optimized by adjusting such reaction parameters as time, temperature and pH.
  • the methods of the present invention are typically performed at or below room temperature at about physiological pH. Because the methods involve the use of proteins, substantially higher temperatures acidity or alkalinity which would substantially modify the tertiary and quaternary structures of the proteins should be avoided. Accordingly, conditions suitable for performing the methods of the present invention generally range from about 1°C to about 37°C, at about physiological pH. The time for performing the methods, of course, will decrease in relation to the increase in temperature at which the methods are performed.
  • anti-donor xenograft antibody material can be administered to the recipient of the xenogeneic transplant prior to and/or during the actual transplant operation.
  • Administration of the antibody material for this purpose would be carried out along the lines and in amounts generally known in this art.
  • a therapeutically effective amount would be predetermined and calculated to achieve the desired effect, i.e., prolonging the survival time of the xenograft.
  • the required dosage will vary with the particular treatment and with the duration of desired treatment. Since the level of preformed anti-donor xenograft antibody in the serum of a patient can readily be determined by routine clinical analysis, dosages can be taylored to the needs of the individual transplant recipient.
  • the continued administration of anti-donor xenograft antibody material post-transplant is contemplated, as needed.
  • said method further comprises administering to said recipient animal a chemical immunosuppressive agent.
  • dosage levels for the anti-donor xenograft antibody material are comparable to levels presented above.
  • Dosage levels for chemical immunosuppressive agent typically fall in the range of about 1 to 1000 milligrams per kilogram of body weight. Ordinarily, 5 to 750 and preferable 10-500 milligrams per kilograms per dose is effective to obtain desired results. Modes of administration as described above are suitable for administration of chemical immunosuppressive agent.
  • Suitable immunosuppressive agents include, for example, Cytoxan
  • cyclophosphamide azathioprine
  • corticosteroids such as prednisone
  • OKT3 OKT3
  • FK506 mycophenolic acid or the morpholinethylester thereof
  • 15-deoxyspergualin rapamycin
  • mizoribine misoprostol
  • IL-2 anti-interluekin-1 receptor antibodies
  • AAG anti-lymphocyte globin
  • a method of inhibiting antibody-mediated rejection of a pig xenograft by a human which comprises modifying antigen expressed by endothelial cells of the pig xenograft, without causing lysis of the cells, to inhibit binding of preformed human anti-porcine xenograft antibody to said antigen, wherein said antigen present in unmodified form induces an antibody-mediated immune response in the human.
  • antigen expresesed by endothelial cells of the pig xenograft are modified by contacting non-lytic, anti-porcine xenograft antibody material with said antigen for a time, at a temperature, and at a pH suitable to bind the antibody material to the antigen, wherein said anti-porcine xenograft antibody material is characterized as immunoreactive with antigen expressed by endothelial cells of the xenograft and capable of inhibiting antibody-mediated rejection of the xenograft and is preferably characterized as a human antibody material.
  • Anti-donor xenograft antibody material useful in the methods of the present invention can be polyclonal or more preferably monoclonol. Several such antibody materials have been described above.
  • a xenograft in a patient comprising contacting said xenograft, prior to transplantation,with anti-donor xenograft antibody material for a time, at a temperature, and at a pH suitable to allow said antibody material to immunoreact with antigen expressed by said xenograft, and then transplanting said xenograft.
  • Such methods can further comprise administering a therapeutically effective dose of said anti-donor antibody material and optionally a chemical immunosuppressive agent to said patient post-transplant H.
  • compositions of the present invention contemplates therapeutic compositions useful for practicing the therapeutic methods described herein.
  • Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with anti-donor xenograft antibody material, as described herein, dissolved or dispersed therein as an active ingredient.
  • the therapeutic composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.
  • pharmaceutically acceptable “physiologically tolerable” and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
  • compositions that contains active ingredients dissolved or dispersed therein are well understood in the art.
  • compositions are prepared as injectables either as liquid solutions or suspensions; however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • the therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein.
  • Pharmaceutically acceptable nontoxic salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like.
  • Also illustrative of such acid addition salts are hydrobromide, sulphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, zinc, iron or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
  • inorganic bases such as, for example, sodium, potassium, ammonium, calcium, zinc, iron or ferric hydroxides
  • organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
  • Physiologically tolerable carriers are well known in the art.
  • Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline.
  • aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.
  • Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.
  • anti-donor xenograft antibodies and antibody materials of the present invention are particularly well suited to isolate antigen expressed by endothelial cells of a xenograft and which are characterized as inducing antibody-mediated rejection of the xenograft by a recipient animal.
  • the present invention provides methods of isolating such antigen comprising contacting anti-donor xenograft antibody or anti-donor xenograft antibody material with endothelial cell membrane lysate of the xenograft for a time and at a temperature and pH suitable to form an immunecomplex comprising said antibody, then seperating said immune-complex from said non-complexed endothelial cell membrane lysate, and seperating said anti-donor xenograft antibody or antibody material from said antigen.
  • antigens include antigen which is characterized as inducing antibody-mediated rejection of the xenograft by humans, particularly those expressed by endothelial cells of porcine xenografts.
  • Such antigens can readily be isolated by immunoprecipitation with the antibody or the antibody material of the present invention.
  • PAEC can be radiolabeled by growing the cells in the presence of radioactive amino acids or radioactive amoino acid precursors, as described for example in Harlow and Lane, Antibodies: A Laboratory Mannual.Cold Sprong Harbor Laboratories, pp. 430-433 (1989) , incorporated herein by reference. Labeled cells can then be lysed as described by Harlow and Lane, pp. 449, supra, incorporated herein by reference, and preferably the membrane lysate seperated for immunoprecitation. Antigen can then be immunoprecipitated from the lysate as described by Harlow and Lane, pp. 465, supra, incorporated herein by reference. Immune-complex can then be seperated on two-dimensional SDS-PAGE gels, extracted and seperated by high pressure liquid chromatography.
  • the choice of the hamster-to-rat as the xenogeneic transplant model was based on the consistently observed patterns of rejection for cardiac xenografts among these animals which are accepted as representing both accelerated and hyperacute patterns of xenograft rejection.
  • the pig-to- rat model was also employed since pigs provide a preferred choice for xenogeneic organ transplant to humans because they can be bred easily, their organs are similar in size and function to human organs, and there is a reduce risk of disease transmission to man from the use of pig organs for transplant as compared to non-human primate organs. All rodent animals brought into the colony are certified virus-free and the colony is monitored regularly for accidental contamination with infectious diseases.
  • the animals are maintained in individual micro-isolator cages, inspected twice daily and fed standard rodent pellet diet and water ad libi tum. Any procedures that might have produced pain or discomfort to these animals was conducted under fluothane and/or pentobarbital anesthesia. The method of euthanasia is by exsanguination.
  • Farm pigs used in the routine surgical training of residents in the Department of Surgery at Cedars Sinai Medical Center were used as a source of pig tissue for these experiments.
  • Intra-abdominal heterotopic ACI rat, hamster, mouse, rabbit and guinea pig cardiac xenograft transplants into rats are performed in accordance with the techniques described in Cramer, D.V. et al. , Transplantation. 53: 303- 308 (1992), incorporated herein by reference.
  • the donor animals are anesthetized with ketamine (100 mg/kg) , xylazine (10 mg/kg) , and atropine (0.05 mg/kg) administered intraperitoneally, and then maintained as necessary on methoxyflurane via inhalation.
  • the venae cavae and the pulmonary veins are ligated with 5-0 silk, and the pulmonary artery and aorta are transected 2-3 mm above their origins in the heart.
  • the heart After perfusion of the ventricles and atria with lactated Ringer's solution (containing 200 units/ml of heparin) , the heart is placed in a saline bath at 4°C. Recipient animals are anesthetized as described above, a midline incision is made, and the great abdominal vessels are dissected free from the left renal vein to the bifurcation.
  • the graft is implanted in the abdominal cavity with end-to-side anastomoses of the donor to recipient aortas and of the pulmonary artery to recipient vena cava in a running continuous suture with 10-0 Novafil on a TE-70 needle. Operative times range from 30 to 45 min, with a success rate of approximately 90%.
  • the grafts are evaluated for function by abdominal palpation and all grafts are removed for examination at the termination of the experiment. At removal the hearts are fixed in 10% buffered formalin for 24 hr and then stored for histological processing.
  • Rejection is considered to have occurred when the xenograft stops functioning, i.e., heart stops beating.
  • Hyperacute rejection is considered to have occurred when the xenograft is rejected within one hour, or more preferably within 10 minutes.
  • Accelerated rejection is considered to have occured when the xenograft has survived for for at least about a
  • hamster heart samples are collected immediately following rejection or at 48 hours in those instances in which hyperacute rejection does not occur.
  • the cardiac xenografts are immediately washed with a 0.9% NaCl solution.
  • One portion of the graft is embedded in O.C.T. compound (Tissue-Tek, Miles Inc. Elkhart, IN) and frozen by immersion in an iso-pentane solution prechilled in dry ice.
  • the remainder of the graft is fixed in 10% buffered formalin and prepared for routine histological examination.
  • Tissue sections are incubated with the antibody of interest, followed by isotype specific antibody and an enzyme-labeled secondary antibody, e.g., mouse monoclonal antibody against rat IgM ⁇ chains (MARM-4, BPS, Inc., Indianapolis, Indiana) , goat-anti-rat complement C 3 antibody (The Binding Site, Birmingham, England) and FITC-conjugated goat-anti-mouse IgG (Caltag Laboratory, Ontario, Canada) may be used.
  • an enzyme-labeled secondary antibody e.g., mouse monoclonal antibody against rat IgM ⁇ chains (MARM-4, BPS, Inc., Indianapolis, Indiana)
  • goat-anti-rat complement C 3 antibody The Binding Site, Birmingham, England
  • FITC-conjugated goat-anti-mouse IgG Caltag Laboratory, Ontario, Canada
  • Rat anti-donor xenograft monoclonal antibodies are prepared by transplantation of LEW rats with hamster heart xenografts or immunization of LEW rats with isolated PAEC in suspension.
  • LEW rats are transplanted with hamster heart xenografts as described in EXAMPLE 1. The xenograft is rejected at Day 4 post-transplant and the recipient spleens harvested for cell fusion at rejection.
  • LEW rats are initially immunized by intraperitoneal injection with 10 5 whole PAEC in PBS followed by a second immunization on day 14 with 10 7 cells in PBS.
  • a third immuniztion of 5 x 10 6 cells is administered at day 21.
  • the rat's spleen is harvested for cell fusion.
  • the splenic lymphocytes (10 8 cells) are mixed with
  • YB2/0 rat myeloma cells (ATCC, Rockville, MD) in serum-free DMEM at a 1:1 ratio, and centrifuged at 500 xg for 5 minutes to pellet the cells. After removing the supernatant, 1 ml of prewarmed (37°C) 50% PEG is added to disrupt the cell pellet. The suspension is swirled for 2 minutes at 37°C, and the mixture diluted with 1 ml of DMEM for 1 minute, followed by the addition of another 1 ml DMEM for one more minute, then 7 ml of DMEM over a course of 2 to 3 minutes. The cells are then centrifuged at 500 xg for 5 min.
  • the cell pellet is gently resuspended in 10 ml of 20% complete DMEM, then diluted to a concentration of 2.5 x 10 6 cells/ml. Aliquots (0.2 ml) of the cell mixture are placed in individual wells (96 well plates) and incubated at 37°C in 7% C0 2 . Hybridoma cells are selected by incubation in HAT medium for a minimum of 2 weeks, beginning on the day after fusion. Supernatants from individual wells are screened for production of IgG and IgM antibodies in an ELISA format as described in EXAMPLE 5 and the ability of the antibodies to immunoreact with antigen expressed by hamster endothelium as described in EXAMPLE 6 or PAEC as described in EXAMPLES 7, below.
  • Clones derived from wells that are positive in the screening process are cloned by limiting dilution in 20% DMEM. Several weeks after the initial cloning, positive clones are subcloned again by limiting dilution at 0.3 cells/well. The antibody secreting clones are then analyzed by the assays described herein.
  • Pig aortic endothelial cells Pig aortic endothelial cells.
  • Pig thoracic aortas are removed using sterile conditions and placed in RPMl/antibiotic medium (RPMI containing penicillin, streptomycin and glutamine (lx antibiotic) ) .
  • RPMl/antibiotic medium RPMI containing penicillin, streptomycin and glutamine (lx antibiotic)
  • Three 50 ml tubes are filled with RPMl/antibiotic medium, approximately 35 mis are needed to cover the length of the aorta.
  • aortas Harvested aortas are each placed in a petri dish. Using the forceps and scissors the connective tissue (CT) and RBCs are completely removed from the outside of the aorta. RBC contamination will interfere with the culture. Once all the CT is removed, the aorta is placed in the first 50 ml tube containing media and shaken slightly to help remove any RBCs inside the aorta. If the aorta looks clean, it is moved on to tube 2 and then tube 3. Each well of a six-well tissue culture plate (Baxter T4133-2, Corning) that has been coated with 2 ml each of 2% sterile gelatin in lx PBS (Sigma G-
  • RPMl/antibiotic media approximately 3 mis
  • FBS FBS
  • the aorta is removed from the third tube and placed in a clean petri dish. The aorta is turned dorsal side up and the aorta cut open longways. A 1.5 cm section of the aorta is gently scraped with surgical blade and the blade is dipped into one well of the 6 well plate. Scraping is repeated in 1.5 cm increments for all six wells. Each well is mixed to help break up the cells. If sheets of cells are seen under a microscope, resuspend more. If no cells are seen, the aorta is scraped again. The plate is placed in C0 2 incubator.
  • Endothelial cells are passaged when they reach confluence. Experiments are performed on cells between passages 4 and 14, preferably using cells from the earlier passage rather than the latter.
  • LCPKl cells (also referred to as minipig kidney cells) can be obtained from the ATCC, Accession No. CRL-1392. Once cells are thawed and rest overnight, the cells are rinsed with serum free media (5 ml for T75 flask, 7 ml for T162) and the media is discarded. Three mililiters lx Trypsin-Edta (Gibco) are added and the cells incubate at 37°C, 6% C0 2 for 3-5 minutes. When 85-95% are floating an equal volume of growth media is added and the cells pelleted at 1500 rpm at room temperature for 5 minutes. Supernatant is discarded and the cells washed in 3-5 ml growth media and pelleted again.
  • Cells are resuspended in 1 ml growth media per flask and incubated at 37°C, 6% C0 2 . Cells are maintained at 37°C in M199 growth media (Gibco, Grand Island, NY) supplemented with 3% fetal calf serum. (Irvine Scientific) The cells are passaged when they reach 90% confluence and are usually ready for use at passages 5 to 10.
  • Lymphocytes are isolated from the spleens of miniature pigs (Charles River Breeding Laboratory,
  • pig spleen Under sterile conditions, 15-20 g of pig spleen is passed through stainless steel sieves into 20-40 ml of RPMI containing antibiotics (300 ⁇ /ml penicillin and 300 ⁇ g/ml streptomycin) , followed by passage through nylon mesh (Tetko, Inc., Monterey Park, CA) .
  • the lymphocytes are isolated by density centrifugation (Histopaque 1077; Sigma Chemical Co., St. Louis, MO), washed 3 times with RPMI, and then pelleted by centrifugation at 1000 xg for absorption studies.
  • the isotype of antibodies presents in the serum of recipient animals, secreted by hybridomas, and binding to tissue or cells the donor, particularly endothelial cells and lymphocytes were characterized and quantified in an ELISA format.
  • the cells are incubated with monoclonal antibodies (1:10) and antibody binding to the target cells is detected using affinity-purified mouse anti-rat IgG or IgM conjugated with alkaline phosphatase (Accurate Chemical and Scientific Corporation, Westbury, NY) .
  • Absorbance at 405 nanometers is determined after the colorimetric reaction is developed for one hour using 1 mg/ml of p-nitrophenyl phosphate and 100 mM diethanolamine in 0.5 mM MgCl 2 (Bio-Rad Laboratories, Richmond, CA) .
  • Hybridoma supernatants are screened for immunoglobulin (IgM) production using ninety-six (96) well flat bottom plates (Corning Costar Corporation, Cambridge, MA) coated with goat rat IgM (Accurate) antibody (1:2500 of 1 mg/ml stock) in IM carbonate-bicarbonate buffer (Sigma Chemical, Saint Louis, MO) and incubated overnight at 4°C. The plates are blocked with 5% BSA, washed, and incubated at room temperature for 1 hour with the undiluted (neat) hybridoma supernatants.
  • IgM immunoglobulin
  • the plates are then washed and incubated with goat ⁇ rat IgM alkaline phosphatase conjugated antibody (1:5000) (Accurate Chemical and Scientific, Westbury, NY) at room temperature for 30 minutes. Absorbances at 405 nanometers are determined after the colorimetric reaction is developed for 30 to 45 minutes using 1 mg/ml of p- nitrophenyl phosphatase and 100 mM diethanolamine in 0.5 mM MgCL 2 (Bio-Rad Laboratories, Richmond, CA) .
  • tissue sections is used as the source of antigen to detect immunoreactivity of anti-hamster xenograft antibodies, anti-rat xenograft antibody material and preformed rat anti-hamster xenograft antibodies.
  • tissue sections for other donor animals can be substituted in the following assay.
  • Frozen tissue sections are prepared as described above in EXAMPLE 2 and incubated with the antibody, serum or antibody material of interest, followed by isotype specific antibody and an enzyme-labeled secondary antibody, e.g., mouse monoclonal antibody against rat IgM ⁇ chain or K chain(MARM-4, BPS, Inc., Indianapolis, Indiana) , goat-anti- rat complement C 3 antibody (The Binding Site, Birmingham, England) and FITC-conjugated goat-anti-mouse IgG (Caltag Laboratory, Ontario, Canada) may be used.
  • an enzyme-labeled secondary antibody e.g., mouse monoclonal antibody against rat IgM ⁇ chain or K chain(MARM-4, BPS, Inc., Indianapolis, Indiana
  • goat-anti- rat complement C 3 antibody The Binding Site, Birmingham, England
  • FITC-conjugated goat-anti-mouse IgG Caltag Laboratory, Ontario, Canada
  • Blocking solution is removed and monoclonal antibody supernatant, antibody material, or human serum (1:10 dilution) is incubated for one hour at room temperature.
  • the wells are washed twice with RPMI 1640 and antibody binding is detected by adding affinity-purified anti-donor isotype-specific secondary antibody conjugated with an enzyme label, e.g., goat anti-rat IgG or IgM antibody conjugated with alkaline phosphatase or goat anti- human IgG or IgM antibody conjugated with alkaline phosphatase (both available from Accurate Chemical and
  • the secondary antibody is allowed to incubate at room temperature for one hour. Following three washes with RPMI 1640, the colorimetric reaction is developed at room temperature for one hour, using 1 mg/ml of p-nitrophenyl phosphate and lOOmM diethanolamine in 0.5M MgCl (Bio-Rad Laboratories, Richmond, CA) Absorbance is read on an automatic micro plate reader at 405nm. A reading of at least two times background or a control, and more preferably at least 2.5 times background or a control is considered positive.
  • the results of the ELISAs to detect immunoreactivity of antibody and antibody material can be compared to similar experiments conducted with the same cells using flow cytometric analysis.
  • Flow cytometric analysis detects surface expressed antigens on cells.
  • the cells of interest (lxlO 6 ) are incubated with the antibody of interest (monoclonal supernatant, serum, antibody material) .
  • the cells are washed and incubated with 100 ⁇ l of a 1/100 dilution (1 mg/ml initial concentration) of FITC-conjugated affinity-purified anti-donor isotype-specific secondary antibody, e.g., mouse anti-rat IgG or IgM (Serotec,
  • This assay measures antibody-mediated, complement- dependent cytotoxicity and is used to monitor antibody or antibody material cytotoxicity for antigen expression on donor animal cells, such as for example, PAEC or hamster lymphocytes.
  • donor animal cells such as for example, PAEC or hamster lymphocytes.
  • 5 x 10 5 donor cells (PAEC or hamster spleen lymphocytes) in RPMI are incubated at room temperature or on ice for 30 minutes with serial two-fold dilutions of the antibody or antibody material of interest (e.g., rat anti-porcine xenograft monoclonal antibody or the rat anti-hamster xenograft monoclonal antibodies) in medium.
  • the antibody or antibody material of interest e.g., rat anti-porcine xenograft monoclonal antibody or the rat anti-hamster xenograft monoclonal antibodies
  • the cells are washed and rabbit serum (Low Tox, Cedarlane Laboratories) is used as a source of complement. Sixty ⁇ l rabbit complement is added to the cells and allowed to incubate for another hour. Propidium iodide is added to the samples, incubated for 5 minutes, and washed with PBS in accordance with Wetzsteon, P.J., et al., A. Hum. Immunol. 35: 93-99 (1992), incorporated herein by reference. The samples are then ready to be read by the FACScan. The uptake of propidium iodide is indicative of cell death. More than about 20% cell death is considered to indicate that the antibody is cytotoxic.
  • rabbit serum Low Tox, Cedarlane Laboratories
  • Rat anti-hamster serum (1:20 dilution) or rat anti-pig serum (1:20 dilution) is employed as positive controls and normal hamster or pig serum as negative controls.
  • the cytotoxic titre of the supernatants are expressed as a reciprocal of the last dilution exhibiting more than 20% cytotoxicity.
  • Aortic endothelial cell or lymphocyte membranes are extracted as described earlier by Tuso, P.J., et al. , Transplantation 56: 651-655 (1993) , incorporated herein by reference. Protein is extracted from the membranes with
  • Triton X-100 0.5% Triton X-100 in 0.15 M NaCl, 1 mM EDTA, 0.062 M Tris, 9.2 mM 6-aminocaproic acid, 1 mM N-ethylmaleimide (NEM) , 1 mM PMSF at 4°C for 24 hours.
  • the extract is precipitated with ethanol at -70°C and the protein content determined by dye-binding assay as described by Smith. P.K., et al. , Proc. Natl. Acad. Sci. USA 85: 4015 (1988), and incorporated herein by reference.
  • Membrane proteins (10 ⁇ g) are fractionated on a SDS- PAGE gel using a discontinuous method using 10% separating and 3% stacking gels. The proteins are then transferred to nitrocellulose filter (8 hours at 200 mA) . The nitrocellulose filters are then incubated with saturating concentrations of the antibody of interest for 1 hour, followed by an alkaline phosphatase-conjugated mouse anti- rat IgM or IgG (Accurate, dilution 1:2500) . The nitrocellulos filters are then developed using alkaline phosphatase substrate kit (Bio-Rad Lab, Richmond, CA) .
  • the molecular weight of the target antigens recognized by rat anti-porcine xenograft monoclonal antibodies are identified by immunoprecipitation, and compared to the molecular weights of the antigens recognized by preformed anti-porcine xenograft antibodies in human serum that react with PAEC.
  • Pig aortic endothelial cells (5x 10 6 ) cultured as described above are harvested using trypsin-EDTA (Gibco-BRL, Gaithersburg,Maryland) , resuspended in fresh RMPI-1640 medium supplemented with 10% FCS and incubated for 30 minutes at 37 ° C to minimize any proteolytic damage to the relevant antigens.
  • the cells are washed with supplemental PBSxl, resuspended in PBS containing 0.5M sodium phosphate buffer, pH 7.4, and labeled with 125 I by adding, over a period of 15 minutes, 0.5 mCi Nal 125 , 200 ⁇ l of 20 ⁇ M lactoperoxidase, (Signman,St.Louis, MO) and 250 ⁇ l 0.03% hydrogen peroxide, and incubating at 4°C for 15 minutes.
  • Radiolabeled cells are washed three times with 15mM Nal in PBS and incubated with monoclonal antibody supernatants for one hour at 4 ° C.
  • the cells are then lysed with double lysis buffer (1% NP-40 and 0.1% SDS) and antigens are precipitated by incubation of the lysate with CNBR-activated Sepharose 4B beads (Pharmacia, Piscataway, NJ) coupled to mouse anti-rat IgG or IgM monoclonal antibodies (Serotec,Oxford, England) .
  • the immunoprecipitated pellet is washed extensively, then denatured in sample buffer (dd H 2 0 4 ml, Tris 1 ml, Glycerol 0.8 ml, 10%, 1.6 ml 2-ME and 0.4 ml 0.05% BPB) .
  • sample buffer dd H 2 0 4 ml, Tris 1 ml, Glycerol 0.8 ml, 10%, 1.6 ml 2-ME and 0.4 ml 0.05% BPB
  • the eluted material is subjected to electrophoresis on a 10% discontinuous polyacrylamide slab gel and transferred to nitrocellulose membrane. Bands were visualized by exposure of dried nitrocellulose blots to Kodak X-Omat film.
  • Example 12 Construction of V H and V L Specific Rat Anti-Donor cDNA Libraries
  • RNA is extracted from hybridoma cells using a method described by Chomczynsky, P. and Sacchi, N. , Analyt Biochem 162:156 (1987), incorporated herein by reference. Briefly, 10 6 hybridoma cells are washed twice in PBS and resuspended in 1 ml of a solution containing; GuSCN, 4M; NaCitrate pH 7.0, 1.5 mM; and Sarcosyl 0.5%. After phenol/chloroform:isoamyl-OH extraction, total RNA is precipitated twice in isopropanol at -70°C for one hour periods. The final pellet is resuspended in 50 ⁇ l DEPC (Sigma Chemical, Saint-Louis, MO) treated deionized water and the concentration of the RNA established in a spectrophotometer.
  • DEPC Sigma Chemical, Saint-Louis, MO
  • oligonucleotides used for PCR amplification and colony hybridization were defined using the PCGene ® software.
  • the oliogonucleotides were synthesized using core support facilities at the Cedars-Sinai Research Institute.
  • Heavy chain ⁇ The first strand of cDNA is transcribed from 3 ⁇ g of total RNA using a C ⁇ primer "RCM1" (SEQ ID NO: 13) and a cDNA synthesis kit according to the manufacturer's instructions (Boerhinger-Mannheim, Indianapolis, IN) . After the synthesis of double-stranded cDNA duplex, a double stranded synthetic linker "SAX" (SEQ ID NO: 14) is ligated to the 5' end of the double-stranded cDNA.
  • CCM1 C ⁇ primer
  • SAX double stranded synthetic linker
  • T4 DNA ligase (Boehringer Mannheim) is added to 5 ⁇ l cDNA sample, 1 ⁇ l SAX/XAS, 2 ⁇ l dH 2 0, and 1 ⁇ l T 4 buffer and incubated at 16°C for 24 hours.
  • the excess linker is removed by microcentrifugation (Microcon-100, Amicon, Beverly, MA) and the purified cDNA used as a template for PCR amplification.
  • Amplification is carried out using SAX (SEQ ID NO: 14) and the "RCM3" C ⁇ primer (SEQ ID NO: 15) as forward and inverse primers, respectively.
  • RCM3 is located upstream of RCM1 on the constant region.
  • Two microliters of cDNA are used in a 25 ⁇ l reaction that contains: RCM3 (50 ng/ ⁇ l) , 1 ⁇ l; SAX (50 ng ⁇ l) , 1 ⁇ l; Tris-HCl, lOmM; MgCl 2 , 1.5mM; KCl, 50mM; dATP, dCTP, dGTP, dTTP, 0.2mM each; and Taq DNA polymerase, 1 unit.
  • the PCR conditions are: denaturation at 94°C for 60 seconds, annealing at 60°C for 60 seconds, and extension a 72°C for 60 seconds; 35 cycles on a DNA Thermal Cycler 480 (Perkin Elmer Cetus, Norwalk, CT) .
  • Ten microliters of the reaction are run on a 1.4% agarose gel to check for amplification products and to confirm the absence of contamination as demonstrated by the lack of a signal when water alone is used as the negative control.
  • One microliter of PCR products is cloned at 12°C for 16 hours into the pCR ® vector of the TA cloning kit ® (Invitrogen, San Diego, CA) in accordance with the manufacture' s instructions.
  • Two microliters of this reaction (10 ng vector) are used to transform "One-Shot E. Coli" by thermic shock according to the manufacturer's instructions (Invitrogen, San Diego, CA) .
  • Two hundred microliters of the transformation reaction are spread on Luria-Bertani petri dishes to which ampicillin, 100 ng/ ⁇ l (Sigma Chemical, Saint-Louis, MO) and X-Gal (50 ⁇ l, 20 mg/ml) are added.
  • Light chain K The synthesis of double stranded cDNA from 3 ⁇ g of total RNA extracted from HAR-1 cells is similar to the method described for the ⁇ chain. The synthesis of the first strand, however, uses the oligonucleotide poly(dT) 15 from the cDNA synthesis kit. A first round of amplification is carried out using SAX (SEQ ID NO 14) and a C ⁇ , primer referred to as "RCK1" (SEQ ID NO 16) as forward and inverse primers, respectively.
  • a "proof-reading" DNA polymerase, ⁇ l tma DNA polymerase (Perkin Elmer) is used to amplify 4 ⁇ l of cDNA in a lOO ⁇ l reaction that contained: 10X Ultma Buffer, IX; MgCl 2 25mM, 1.5mM; dATP, dCTP, dGTP, dTTP, 40 ⁇ M each; SAX (50 ng/ ⁇ l) , 4 ⁇ l; RCK1 (50 ng/ ⁇ l) , 4 ⁇ l; Ultma AND polymerase, 0.5 unit.
  • the PCR conditions are: denaturation at 94°C for 45 seconds, annealing at 55°C for 1 second, and extension at 72°C for 60 seconds; 30 cycles on a DNA Thermal Cycler 480 (Perkin Elmer Cetus, Norwalk, CT) .
  • the PCR products are fractionated on a 1.2% low melting point agarose gel (Gibco BRL, Gaithersburg, MD) and the cDNA fragments of 492 to 1107 bp purified by phenol/chloroform extraction-ethanol precipitation, resuspended in 15 ⁇ l Tris- EDTA and subjected to another round of PCR amplification.
  • RCK3 SEQ ID NO 17
  • This second "nested" amplification uses the enzyme Taq as DNA polymerase so as to generate PCR products with unpaired deoxyadenosine on their 3' ends, a condition necessary for efficient cloning into the pCR ® vector.
  • the PCR conditions are as above for Taq, except that the number of cycles is limited to 25.
  • One microliter of PCR products are cloned in the pCR ® vector, in accordance with the manufacturer's direction, and E. coli bacteria transformed as described above.
  • Recombinant colonies are first identified by color screening based on the demonstration of the loss of ⁇ - complementation. White colonies are subsequently screened by PCR using SAX/RCM3 and SAX/RCK3 as primers for the ⁇ and library, respectively. Briefly, each individual colony is harvested with a sterile tooth-pick, resuspended in 100 ⁇ l sterile double distilled water, and incubated at room temperature for 30 minutes.
  • Each tube is vortexed briefly and 4 ⁇ l used as a template in a 10 ⁇ l reaction that includes: SAX (50 ng/ ⁇ l), 0.8 ⁇ l; anti-sense primer (50 ng/ ⁇ l) , 0.8 ⁇ l; Tris-HCl, lOmM; MgCl 2 , 1.5mM; KCl, 50mM; dATP, dCTP, dGTP, dTTP, 0.2mM each; and 1 unit of Tag DNA polymerase.
  • the PCR conditions are: denaturation at 94°C for 20 seconds, annealing at 55°C for 60 seconds, and extension at 72°C for 60 seconds; 28 cycles on a GeneAmp PCR system 9600 (Perkin Elmer Cetus, Norwalk, CT) . Colonies of interest are identified by the demonstration of an insert of the expected size ( ⁇ 600 bp for SAX/RCM3 and 460 bp for SAX/RCK3) . Within each library, a minimum of 4 positive colonies are used to obtain cDNA sequence information.
  • Example 14 Plasmid DNA Extraction and Sequencing
  • Plasmid DNA is extracted by alkaline lysis according to Sambrook, J. , et al. , Molecular Cloning. A Laboratory Manual Cold Spring Harbor Laboratory Press (1989) and sequenced on both strands with the Sanger dideoxynucleotide chain termination method as used in the Sequenase Plasmid Sequencing kit (United States Biochemicals, Cleveland, OH) .
  • LEW liver is harvested and digested for 16 hours at 55°C in a solution of proteinase K, 10 mg/ml; Tris, 50 mM;- EDTA, 100 mM; NaCl, lOOmM and SDS 1%. After phenol/chloroform extraction the DNA is precipitated with ethanol. Ten nanograms of DNA are amplified with Ultma DNA polymerase using the parameters already described for that enzyme. Amplification primers were chosen based on the sequence information ' for V H segment of HAR-1 ( Figure 1) .
  • the sense primer referred to here as "RVHl" (SEQ ID NO 7) is designed to anneal immediately before the initiation codon.
  • the anti-sense primer referred to here as "RVH2" (SEQ ID NO 8) , is designed to anneal on framework region 3, downstream of the first two complementarity determining regions.
  • the PCR conditions are as already described for the Ultma enzyme.
  • the amplification products are treated with Taq DNA polymerase so as to add unpaired deoxyadenosine to the 3 ' end of the molecules and to allow for subsequent cloning in the pCR ® vector.
  • amplification products generated with Ultma are fractionated by electrophoresis on a 1.4% LMP agarose gel, purified by phenol/chloroform, precipitated in ethanol and resuspended in 20 ⁇ l Tris-EDTA.
  • One unit of Taq DNA polymerase and 4 ⁇ l ImM dATP are added and the reaction carried out at 72°C for 10 minutes.
  • the following method of making anti-donor xenogen antibody material is described in term of a the generation and screening of a human IgM heavy chain, human IgK light chain Fab library displayed through the use of filimentous phage encoded by the SurfZAPTM Vector (Stratagene, La Jolla, CA) and the SurfZAPTM Vector Kit, both available from Stratagene (La Jolla, CA) .
  • the SurfZAPTM Vector Stratagene, La Jolla, CA
  • the SurfZAPTM Vector Kit both available from Stratagene
  • Peripheral blood or perferably splenic lymphocytes are isolated from a human transplant patient who has recieved a porcine xenograft. For example, biopsy tissue is minced and then incubated at 37°C for 30 minutes in sterile culture medium (RPMI 1640, 10% FCS, and antibiotics) with 20 ⁇ g/ml collagenase, 20 ⁇ g/ml hyaluronidase, and 0.1% DNase. Tissue is then titrated through an 18 gauge needle until a cloudy suspension is achieved. After washing, the resultant single cell suspension is centrifuged on a Ficoll-Hypaque gradient to obtain mononuclear cells. Peripheral blood mononuclear cells ("PBMC”) are isolated directly by Ficoll-Hypaque fractionation.
  • PBMC Peripheral blood mononuclear cells
  • Isolated lymphocytes are cultured at 37°C in a humidified atmosphere of 5% C0 2 :95% air for 12 days at a concentration of 2 x 10 6 cells/ml in RPMI 1640 (Irvine Scientific, Santa Ana, CA) supplemented with 10% fetal bovine serum and antibiotics. Supernatant is analyzed for concentrations of total serum IgM by a standard ELISA method. Briefly, wells of microtiter plates (Costar, Desion, CA) are coated overnight (4°C) with goat anti-human IgM (Accurate Chemical and Scientific Corp., Westbury, NY) diluted in carbonate- bicarbonate buffer, pH 9.6 (Sigma, St. Louis, MO) .
  • nucleotide sequences encoding the immunoglobulin protein CDRs are highly variable. However, there are several regions of conserved sequences in nucleotide sequences encoding human immunoglobulins that flank the V region domains of either the light or heavy chain, for instance and that contain substantially conserved nucleotide sequences, i.e., sequences that will hybridize to the same primer sequence. Polynucleotide synthesis (amplification) primers that hybridize to the conserved sequences and incorporate restriction sites into the DNA homolog produced that are therefore suitable for operatively linking the synthesized DNA fragments to a vector are employed.
  • the primers are designed so that the resulting DNA homologs produced can be inserted into an expression vector in reading frame with the upstream translatable DNA sequence at the region of the vector containing the first restriction site.
  • linkers containing the desired restriction site e.g., SEQ ID NO: 33
  • SEQ ID NO: 33 can be blunt end ligated to the end of the Ig DNA fragment so that the resulting DNA homologs produced can be inserted into an expression vector in reading frame with the upstream translatable DNA sequence at the region of the vector containing the first restriction site.
  • Amplification with the primers described herein is performed on cDNA templates produced from mRNA isolated from lymphocytes isolated as described above. V ⁇ Primers.
  • primers are designed to introduce cohesive termini compatible with directional ligation into one of the two unique restriction sites (NotI or Spel) of the SurfZAP vector.
  • the 5 ' primers should be chosen to be complimentary to the first strand cDNA in the conserved and N-terminus region (anti-sense strand) .
  • Listed in SEQUENCE ID Nos: 26 through 31 are exemplary Ig family specific heavy chain Ig primers which can be engineered to incorporate the desired restriction site or used with restriction site encoding linkers.
  • V H amplification primers including the unique 3 ' primer are designed to be complimentary to a portion of the first constant region domain of the ⁇ l heavy chain mRNA (SEQUENCE ID No: 32) . These primers will produce DNA homologs containing polynucleotides coding for amino acids from the V H region and the first constant region domains of the heavy chain. These DNA homologs can therefore be used to produce Fab fragments rather than F v .
  • Additional unique 3 ' primers designed to be hybridized to similar regions of another class of immunoglobulin heavy chain such as IgG, IgE and IgA are contemplated.
  • Other 3' primers that hybridize to a specific region of a specific class of CH- L constant region and are adapted for transferring the V H region amplified using this primer to an expression vector capable of expressing those V H region with a different class of heavy or light chain constant regions are also contemplated.
  • Either the V H or the V c should contain a third restriction, unique from either the first or second restrictions site, to provide a means for directional ligating heavy and light chain sequences together for subesequent insert into the phagemeid vector.
  • Amplification is performed in six separate reactions, each containing one of the 5' family specific (VH1 - VH6) primers and a 3 ' primer.
  • the 5 ' primers preferably incorporate a Not I site and the 3 ' primers preferably incorporate a FSI 1 restriction site, for the insertion of the V H DNA homolog into the phagemid expression vector and ligation to the Ig kappa light chain sequence, respectively.
  • V ⁇ Primers The nucleotide sequences encoding the V ⁇ CDRs are highly variable. However, there are several regions of conserved sequences that flank the V ⁇ CDR domains including the J ⁇ , V ⁇ framework regions and V ⁇ leader/promoter. Therefore, amplification primers are constructed that hybridize to the conserved sequences and incorporate restriction sites that allow directional ligation of the amplified fragment to the heavy chain fragment.
  • the 5' primers are designed to be complimentary to the first strand cDNA in the conserved N-terminus region. These primers preferably introduce a FSI 1 restriction endonuclease site to allow the V ⁇ DNA homolog to be ligated to the V H homolog.
  • the 3' V ⁇ amplification primer is designed to hybridize to the constant region of the kappa mRNA and to introduce the Spe I restriction endonuclease site required to insert the V ⁇ DNA homolog into the SurfZAP vector. These primers allow a DNA homolog to be produced containing polynucleotide sequences coding for constant region amino acids of the kappa chain. These primers make it possible to produce a Fab fragment rather than a Fv. Amplification with these primers is performed in separate reactions, each containing one of the family specfic 5' primers and one of the 3' primers.
  • Amplification primers designed to amplify human light chain variable regions of the lambda isotype are also contemplated.
  • RNA is extracted from 1.15 x 10 7 lymphocytes using standard guanadinium isothiocynate extraction protocols. See, for example, Chomcynski, P. and Saochi, N. , Anal. Biochem. 162:156-159 (1987), incorporated herein by reference.
  • the mRNA In preparation for PCR amplification, the mRNA, prepared above, is used as a template for cDNA synthesis by a primer extension reaction.
  • 10 ⁇ g RNA is reverse transcribed to single-stranded cDNA using 1 ⁇ g oligo-dT primer with 10 mM dithiothreitol, RNasinTM (a protein RNAse inhibitor of Promega Corporation, Madison, WI) , 25 mM each dATP, dCTP, dGTP, dTTP, lx reverse transcriptase buffer (Bethesda Research Laboratories, Bethesda, MD) , and 2 ⁇ l (two hundred units) reverse transcriptase (Bethesda Research Laboratories,TM Bethesda, MD) in 50 ⁇ l volume for 10 minutes at room temperature followed by 50 minutes at 42°C. Following a 5 minute 90°C heat kill and 10 minutes on ice, the reaction was treated with 1 ⁇ l (one unit) R
  • the cDNA generated above is amplified using the polymerase chain reaction ("PCR") method.
  • PCR polymerase chain reaction
  • Family specific variable region and isotype specific constant region primers as described above are used to create heavy chain IgM V H 1-V H 6 family-specific and light chain V ⁇ l-V ⁇ 3 family-specific libraries.
  • PCR amplification is performed in a 50 ⁇ l reaction containing the products of the reverse transcription reaction (about 100 ⁇ g of the cDNA/RNA hybrid), 50 ng of 5' V H primer, 50 ng of the 3' primer, 500mM of the mixture of dNTP's, 5 mM KCl, 100 mM Tris-HCl buffer at pH 8.3, and .25 units of Taq DNA polymerase (Boehringer Mannheim, Indianopolis, Indiana) .
  • the reaction mixture is subjected to 30 cycles of amplification using a DNA Thermal Cycler 480 (Perkin Elmer Cetus, Norwalk, CT)
  • a DNA Thermal Cycler 480 Perkin Elmer Cetus, Norwalk, CT
  • Each amplification cycle included denaturing of cDNA at 94°C for 15 minutes, followed by annealing of primers at 52°C for 50 minutes, and amplification at 72°C for 90 minutes. This is followed by a 10 minute extension at 72°C.
  • heavy chain and light chain libraries are separately pooled and gel purified on 0.8% Seaplaque GTG Agarose (FMC, Rockland, ME) according to the manufacturer's directions.
  • Equal portions of the products from each light chain primer extension reaction and each heavy chain primer extension reaction is mixed to create randomization of subsequent V H and V ⁇ ligation.
  • the mixed products are digested with FPI 1 restriction endonuclease. (All restriction enzymes are available from Boehringer-Mannheim, Indianapolis, IN.) Digested products are again gel purified as described above, and the region of the gel containing DNA fragments of appropraite size are excised, electroeluted into a dialysis membrane and ethanol precipitated. The resulting DNA fragments are again mixed to create randomization and liogated to one another, and gel purified as described above. Finally, ligated DNA is double-digested with Not 1 and Spe 1 which will represent a repertoire of polypeptide genes having cohesive termini adapted for directional ligation into the to create an insert that can be directionally ligated into the SurfZAP vector.
  • the SurfZAP vector is prepared in accordance with the manufacturer's direction for inserting the V H -V K sequence.
  • Escherichia coli provided in the SurfZAP Cloning Kit (Stratagene, La Jolla, CA) are transformed with the SurfZAP vector containing the Ig library in accordance with the manufacturer's directions. Transformants are selected by antibioic resistance and enriched by growth in liquid cultures. d . Panning
  • Panning is performed to select for phage displayed Fab that bind PAEC.
  • PAEC cells are grown in in RPMI 1640 growth medium supplemented with 10% FBS and antibiotics to approximately 4 million cells, preferably at a low passage ( ⁇ 2) , in a T75 tissue culture flask. The cells are rinsed 5-10 times with PBS to remove all medium. Non-specific binding is blocked with PBS supplemented with 3% BSA for one hour at 37°C. The cells are aspirated to remove all blocking agent and about 10 11 phage in SM broth are added to the cells and gently rocked at 37°C for about 2-3 hours. Cells are washed about 10 times with PBS supplemented with .5% Tween 20 to remove unbound phage.
  • Phage which bind the cells are eluted by incubating cells with 2 ml of .IM HCl at pH 2.2 with BSA to a concentration lmg/ml (w/v) for about 10 minutes at room temperatire while gently rocking the flask.
  • the reaction is neutrilized with 2 M Tris base.
  • the number of phage eluted is monitored by CFU.
  • Eluted phage are amplified by reinfecting 2 ml E. coli XL-Blue in growth medium supplemented with tetracycline with 50 ⁇ l eluted phage.
  • Ten ml SB with carbenicillin is added to select for phagemids. Panning repeated until there was at least 100 fold enrichment.
  • aliquots of the original library are re-panned in parallel with each cycle of enrichment to control for daily fluctuations in phage recovery.
  • Enrichment is calculated by ratio of phage on vs. off and compared to the unenriched library run on the same day.
  • each round of panning is conducted against PAEC from the same individual and PAEC from another individual as a control.
  • GCA AGA CCT TCC TAT AGC AGC TAC TTT GAT TAC TGG GGC CAA GGA GTC 336 Ala Arg Pro Ser Tyr Ser Ser Tyr Phe Asp Tyr Trp Gly Gin Gly Val 100 105 110
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • GCA AAA GCA ACT GGG AGC TTT GAT TAC TGG GGC CAA GGA GTC ATG GTC 336 Ala Lys Ala Thr Gly Ser Phe Asp Tyr Trp Gly Gin Gly Val Met Val 100 105 110
  • Trp Met Gly Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • AAA ATG AAC AAT CTG CAA ACT GAA GAC ACG GCC ATG TAC TTC TGT GCC 288 Lys Met Asn Asn Leu Gin Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala 85 90 95 AGA GGA GGA GTG GGG TTT GAT TTC TGG GGC CAA GGA GTC ATG GTC ACA 336 Arg Gly Gly Val Gly Phe Asp Phe Trp Gly Gin Gly Val Met Val Thr 100 105 110
  • MOLECULE TYPE cDNA to mRNA
  • HYPOTHETICAL NO
  • ORIGINAL SOURCE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compositions et procédés utiles à l'inhibition du rejet des greffons hétérologues induits par des anticorps chez des receveurs de transplants hétérologues. Sont également décrits de nouveaux procédés de transplantation hétérologue. L'invention concerne également des compositions favorisant le rejet des greffons hétérologues par l'action des anticorps. Des procédés permettant d'isoler des antigènes exprimés par les cellules endothéliales d'un greffon hétérologue, favorisant le rejet des greffons hétérologues induits par les anticorps sont également présentés.
PCT/US1996/006804 1995-05-15 1996-05-14 Composition et procede d'inhibition du rejet des greffons heterologues WO1996036358A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96915749A EP0827409A1 (fr) 1995-05-15 1996-05-14 Composition et procede d'inhibition du rejet des greffons heterologues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44062195A 1995-05-15 1995-05-15
US440,621 1995-05-15

Publications (1)

Publication Number Publication Date
WO1996036358A1 true WO1996036358A1 (fr) 1996-11-21

Family

ID=23749499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006804 WO1996036358A1 (fr) 1995-05-15 1996-05-14 Composition et procede d'inhibition du rejet des greffons heterologues

Country Status (3)

Country Link
EP (1) EP0827409A1 (fr)
CA (1) CA2221234A1 (fr)
WO (1) WO1996036358A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013947A1 (fr) * 1999-08-26 2001-03-01 Absorber Ab Reduction de l'immunogenicite de greffons non humains
US20100239594A1 (en) * 2005-08-03 2010-09-23 Vidadi Yusibov Compositions and methods for production of immunoglobulins
WO2011109298A3 (fr) * 2010-03-02 2011-11-24 Abbott Laboratories Protéines thérapeutiques de liaison à dll4
US9132190B2 (en) 2009-08-29 2015-09-15 Abbvie Inc. Therapeutic DLL4 binding proteins
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
CN112480255A (zh) * 2007-07-09 2021-03-12 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119019554A (zh) * 2023-05-25 2024-11-26 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRANSPLANTATION PROCEEDINGS, June 1994, Vol. 26, No. 3, WU et al., "Distribution of Xenogeneic Target Antigens Detected by a Monoclonal Antibody Capable of Inducing Hyperacute Rejection of Hamster Cardiac Xenografts in Rats", pages 1382-1383. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013947A1 (fr) * 1999-08-26 2001-03-01 Absorber Ab Reduction de l'immunogenicite de greffons non humains
US20100239594A1 (en) * 2005-08-03 2010-09-23 Vidadi Yusibov Compositions and methods for production of immunoglobulins
US8962278B2 (en) * 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US11976127B1 (en) 2007-07-09 2024-05-07 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US12173080B1 (en) 2007-07-09 2024-12-24 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US12145997B2 (en) 2007-07-09 2024-11-19 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US12098211B2 (en) 2007-07-09 2024-09-24 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11987638B1 (en) 2007-07-09 2024-05-21 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11987637B1 (en) 2007-07-09 2024-05-21 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
CN112480255A (zh) * 2007-07-09 2021-03-12 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
US9469688B2 (en) 2009-08-29 2016-10-18 Abbvie Inc. Therapeutic DLL4 binding proteins
US9132190B2 (en) 2009-08-29 2015-09-15 Abbvie Inc. Therapeutic DLL4 binding proteins
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9469689B2 (en) 2010-03-02 2016-10-18 Abbvie Inc. Therapeutic DLL4 binding proteins
US9115195B2 (en) 2010-03-02 2015-08-25 Abbvie Inc. Therapeutic DLL4 binding proteins
WO2011109298A3 (fr) * 2010-03-02 2011-11-24 Abbott Laboratories Protéines thérapeutiques de liaison à dll4

Also Published As

Publication number Publication date
CA2221234A1 (fr) 1996-11-21
EP0827409A1 (fr) 1998-03-11

Similar Documents

Publication Publication Date Title
US7429647B2 (en) Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
US7597892B2 (en) Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15)
US7556803B2 (en) Method for treating multiple myeloma
US6160099A (en) Anti-human αv β3 and αv β5 antibodies
US9089557B2 (en) Human antibodies against Pseudomonas aeruginosa LPS derived from transgenic xenomouse
US6790938B1 (en) Anti-GPIIb/IIIa recombinant antibodies
JPH03501927A (ja) ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
KR20010034554A (ko) 치료제로서의 ｃｄ147 결합 분자
JP2003277293A (ja) 移植片拒絶反応抑制剤
JP2000500961A (ja) 新規のｃｔｌａ４／ｃｄ２８リガンド及びその使用
PL170321B1 (pl) Sposób wytwarzania nowej czasteczki wiazacej CD25 PL PL PL PL PL PL
US7223729B2 (en) Methods of treating allergy by administering a CD200 protein
WO1996036358A1 (fr) Composition et procede d'inhibition du rejet des greffons heterologues
US5728812A (en) Anti-idiotypic antibody composition for inhibiting acute complement-mediated cytotoxicity
EP0942750B1 (fr) Agents de fixation anti-classe ii du cmh, utilises dans les heterogreffes
US20030235586A1 (en) Human antibodies specific for interleukin 15 (IL-15)
Tanaka et al. Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.
JP2528549B2 (ja) ヒトｉｌ―２レセプタ―重鎖に結合する新規モノクロ―ナル抗体
Casey Mechanisms Responsible for Indefinite Survival of Cardiac Allografts Induced by R73 Monoclonal Antibody in a Rat Model
JP2001510027A (ja) Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2221234

Country of ref document: CA

Ref country code: CA

Ref document number: 2221234

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996915749

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996915749

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996915749

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载